A Phase 3 interventional study of MenABCWY and Saline in Meningococcal Vaccine, sponsored by Pfizer. Completed at 75 sites in 4 countries. Open to participants aged 10 Years to 25 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-08.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is examining safety and immunogenicity of 2 doses of Trumenba administered on a 0-,6- month schedule. This trial is also studying safety and immunogenicity of a meningococcal pentavalent vaccine.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ACWY Naive subjects, MenABCWY/Saline
Biological: MenABCWY · Biological: Saline
ACWY Naive subjects, rLP2086/MenACWY-CRM
Biological: rLP2086 · Biological: MenACWY-CRM
ACWY Experienced subjects, MenABCWY/Saline
Biological: MenABCWY · Biological: Saline
ACWY Experienced subjects, rLP2086/MenACWY-CRM
Biological: rLP2086 · Biological: MenACWY-CRM
N meningitidis group A, B, C, W, and Y vaccine
Placebo
Drug pages: MenB-FHbp vaccine · 4CMenB vaccine
Bivalent recombinant lipoprotein 2086 vaccine
meningococcal group A, C, W-135, and Y conjugate vaccine
Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome. Analysis for this outcome measure was planned for combined Group 2 and 4.
Time frame: 1 month after Vaccination 2
Stage1: Percentage of Participants With Fold Rise >=4 in hSBA for Each of the 4 Primary MenB Test Strains From Baseline to 1 Month After Vaccination 2 (Group 2 and 4 Combined)
The 4-fold increase: a) participants with baseline hSBA titer below limit of detection (LOD or an hSBA titer \<1:4), response was defined as hSBA titer \>=1:16 or LLOQ (whichever titer is higher); b) Participants with baseline hSBA titer \>= LOD and \< LLOQ, response was defined as hSBA titer \>= 4 times the LLOQ; c) participants with baseline hSBA titer \>= LLOQ, response was defined as hSBA titer \>=4 times baseline titer. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Analysis for this outcome measure was planned for combined Group 2 and 4.
Time frame: From Baseline (blood draw prior to Vaccination 1) to 1 month after Vaccination 2
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: 7 days after Vaccination 1
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: 7 days after Vaccination 2
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
Time frame: 7 days after Vaccination 1
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
Time frame: 7 days after Vaccination 2
Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 1 (Group 2 and 4 Combined)
Time frame: 7 days after Vaccination 1
Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 2 (Group 2 and 4 Combined)
Time frame: 7 days after Vaccination 2
Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: 30 days after Vaccination 1
Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: 30 days after Vaccination 2
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: 30 days after any vaccination
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1 (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 days after Vaccination 1
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 days after Vaccination 2
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 days after any vaccination
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1 (Group 2 and 4 Combined)
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: 30 days after Vaccination 1
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: 30 days after Vaccination 2
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: 30 days after any Vaccination
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Follow-up Phase (Group 2 and 4 Combined)
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Throughout the Stage 1 (Group 2 and 4)
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: 30 days after Vaccination 1
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: 30 days after Vaccination 2
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: 30 days after any vaccination
Stage1: Percentage of Participants With at Least 1 AE During Vaccination Phase (Group 2 and 4 Combined)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1 (Group 2 and 4 Combined)
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
Time frame: 30 minutes after Vaccination 1
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2 (Group 2 and 4 Combined)
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
Time frame: 30 minutes after Vaccination 2
Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined)
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage2: Percentage of Participants With Local Reactions Within 7 Days After Booster Vaccination: Group 1 Through Group 4
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: 7 days after booster vaccination
Stage2: Percentage of Participants With Systemic Events Within 7 Days After Booster Vaccination: Group 1 Through Group 4
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
Time frame: 7 days after booster vaccination
Stage2: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Booster Vaccination: Group 1 Through Group 4
Time frame: 7 days after booster vaccination
Stage2: Percentage of Participants With at Least 1 SAE During Booster Vaccination Phase: Group 1 Through Group 4
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was included in results of Group 4.
Time frame: Booster vaccination phase: From booster vaccination through 1 month after booster vaccination
Stage2: Percentage of Participants With at Least 1 SAE During the Booster Follow-up Phase: Group 1 Through Group 4
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: Booster follow-up phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)
Stage2: Percentage of Participants With at Least 1 SAE Throughout Booster Phase: Group 1 Through Group 4
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was reported in result of outcome measure 37 for Group 4. Subsequently correction was made by the trial site and not included in subsequent phase/results. Hence, that 1 participant is not included in results of Group 4 here.
Time frame: Throughout Booster phase: From booster vaccination through 6 months after booster vaccination
Stage2: Percentage of Participants With at Least 1 Medically Attended AE During Booster Vaccination Phase: Group 1 Through Group 4
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Booster vaccination phase: From booster vaccination through 1 month after booster vaccination
Stage2: Percentage of Participants With at Least 1 Medically Attended AE During the Booster Follow-up Phase: Group 1 Through Group 4
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Booster Follow-up Phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)
Stage2: Percentage of Participants With at Least 1 Medically Attended AE Throughout Booster Phase: Group 1 Through Group 4
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Throughout Booster Phase: From booster vaccination through 6 months after booster vaccination
Stage2: Percentage of Participants With at Least 1 NDCMC During Booster Vaccination Phase: Group 1 Through Group 4
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination
Stage2: Percentage of Participants With at Least 1 NDCMC During the Booster Follow-up Phase: Group 1 Through Group 4
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Booster Follow-up Phase: From 1 month after booster vaccination through 6 months after booster vaccination (up to 5 months)
Stage2: Percentage of Participants With at Least 1 NDCMC Throughout Booster Phase: Group 1 Through Group 4
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Throughout Booster Phase: From booster vaccination through 6 months after booster vaccination
Stage2: Percentage of Participants With at Least 1 AE During Booster Vaccination Phase: Group 1 Through Group 4
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination
Stage2: Percentage of Participants With at Least 1 Immediate AE After Booster Vaccination: Group 1 Through Group 4
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
Time frame: 30 minutes after booster vaccination
Stage2: Number of Participants Who Missed School/Work Due to AE After Booster Vaccination: Group 1 Through Group 4
Time frame: Booster Vaccination Phase: From booster vaccination through 1 month after booster vaccination
Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
Time frame: 1 month after Vaccination 2
Stage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for All 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for all 4 primary MenB test strains was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
Time frame: 1 month after Vaccination 2 (Vacc 2)
Stage1: hSBA Geometric Mean Titers (GMTs) for All 4 Primary MenB Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined)
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5 \* LLOQ for analysis. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
Time frame: 1 month after Vaccination 2 (Vacc 2)
Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for 10 Secondary MenB test strains combined (LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16) was reported in this outcome measure.
Time frame: 1 month after Vaccination 2 (Vacc 2)
Stage1: Percentage of Participants With hSBA Titer Level >= 1:4, >= 1:8, >= 1:16, >= 1:32, >= 1:64, >= 1:128 for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for each of the 10 secondary MenB test strains was reported in this outcome measure. 10 secondary MenB test strains were PMB3175 (A29), PMB3010 (A06), PMB824 (A12), PMB3040 (A07), PMB1672 (A15), PMB1989 (A19), PMB648 (B16), PMB866 (B09), PMB1256 (B03) and PMB431 (B15).
Time frame: 1 month after Vaccination 2 (Vacc 2)
Stage1: hSBA Geometric Mean Titers (GMTs) for Each of the 10 Secondary MenB Test Strains 1 Month After Vaccination 2 (Group 2 and 4 Combined)
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
Time frame: 1 month after Vaccination 2 (Vacc 2)
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=LLOQ for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
Time frame: 1 month after Vaccination 1
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains 1 Month After the Vaccination 1: Groups 1, 2, 3 and 4
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.
Time frame: 1 month after Vaccination 1
Stage1: hSBA Geometric Mean Titers (GMTs) for ACWY Test Strains 1 Month After Vaccination 1: Groups 1, 2, 3 and 4
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
Time frame: 1 month after Vaccination 1
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ, Whichever is Higher) for ACWY Test Strains 1 Month After the Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>= LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
Time frame: For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2
Stage1: Percentage of Participants With MenA, MenC, MenW, and MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and, >=1:128 for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4, and 1 Month After Vaccination 2 in Groups 1 and 3
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.
Time frame: For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2
Stage1: hSBA GMTs for ACWY Test Strains 1 Month After Vaccination 1 in Groups 2 and 4 and 1 Month After Vaccination 2 in Groups 1 and 3
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
Time frame: For Group 2 and 4: 1 month after Vaccination 1; For Group 1 and 3: 1 month after Vaccination 2
Stage1: Percentage of Participants With hSBA Titer Level >= LLOQ for 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
Time frame: 1 month after Vaccination 2 (Vacc 2)
Stage1: Percentage of Participants With >=4 Fold Rise in hSBA for 4 Primary MenB Strains and Composite Response (hSBA >=LLOQ for All 4 Primary MenB Strains Combined) From Baseline-1 Month After Vaccination 2 (Group 1 and 3 Combined;Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
Time frame: Baseline to 1 month after Vaccination 2
Stage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains From 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for all 4 primary MenB test strains was reported in this outcome measure.
Time frame: 1 month after Vaccination 2
Stage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains 1 Month After Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
Time frame: 1 month after Vaccination 2
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW and hSBA-MenY Titers >=1:8 (or LLOQ) for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Stage1: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>= :8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.
Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Stage1: hSBA GMTs for ACWY Test Strains Before Vaccination 1 and Before Vaccination 2: Groups 1, 2, 3 and 4
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. Confidence intervals were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the concentrations, or the mean of the ratio.
Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Stage1: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Stage1: Percentage of Participants With hSBA Titers >=1:4, >=1:8, >=1:16, >=1:32, >=1:64, and >=1:128 for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for each of the 4 primary MenB test strains was reported in this outcome measure.
Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Stage1: hSBA GMTs for Each of the 4 Primary MenB Test Strains Before Vaccination 1 and Before Vaccination 2 (Group 1 and 3 Combined; Group 2 and 4 Combined)
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. CIs were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the hSBA titers.
Time frame: Before Vaccination 1 (Vacc 1) [Day 1], Before Vaccination 2 (Vacc 2) [173 to 194 Days After Visit 1]
Stage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or LLOQ if Higher) for ACWY Test Strains During Persistence Phase: Groups 1, 2, 3 and 4
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY Test Strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
Time frame: 12, 24, 36 and 48 months after Vaccination 2 (Vacc 2)
Stage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains During Persistence Phase (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
Time frame: 12, 24, 36 and 48 months after Vaccination 2 (Vacc 2)
Stage2: Percentage of Participants With hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY Titers >=1:8 (or >=LLOQ if Higher) for ACWY Test Strains 1 Month After Booster Vaccination: Groups 1 and 3 (Separately)
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure. Analysis was planned for Group 1 and 3 separately.
Time frame: 1 month after booster vaccination
Stage2: Percentage of Participants With hSBA Titer Level >=LLOQ for 4 Primary MenB Test Strains 1 Month After Booster Vaccination (Group 1 and 3 Combined; Group 2 and 4 Combined)
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
Time frame: 1 month after booster vaccination
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1: Group 1 and Group 3
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: 7 days after Vaccination 1 (Vacc 1)
Stage1: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 2: Group 1 and Group 3
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: 7 days after Vaccination 2 (Vacc 2)
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 1: Group 1 and Group 3
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
Time frame: 7 days after Vaccination 1 (Vacc 1)
Stage1: Percentage of Participants With Systemic Events Within 7 Days After Vaccination 2: Group 1 and Group 3
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
Time frame: 7 days after Vaccination 2 (Vacc 2)
Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 1: Group 1 and Group 3
Time frame: 30 days after Vaccination 1
Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 2: Group 1 and Group 3
Time frame: 30 days after Vaccination 2
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 1: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: 30 days after Vaccination 1
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 2: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: 30 days after Vaccination 2
Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: 30 days after any vaccination
Stage1: Percentage of Participants With at Least 1 SAE During the Vaccination Phase: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1: Group 1 and Group 3
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 days after vaccination 1
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2: Group 1 and Group 3
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 days after vaccination 2
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination: Group 1 and Group 3
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: 30 days after any vaccination
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase: Group 1 and Group 3
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase: Group 1 and Group 3
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1: Group 1 and Group 3
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 1: Group 1 and Group 3
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: 30 days after vaccination 1
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 2: Group 1 and Group 3
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: 30 days after vaccination 2
Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Any Vaccination: Group 1 and Group 3
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: 30 days after any vaccination
Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Vaccination Phase: Group 1 and Group 3
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Follow-up Phase: Group 1 and Group 3
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Stage 1 Follow-up phase: From 1 month after Vaccination 2 through 6 months after Vaccination 2 (5 Months)
Stage1: Percentage of Participants With at Least 1 NDCMC Throughout the Stage 1: Group 1 and Group 3
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
Time frame: Throughout Stage 1: From the Vaccination 1 through 6 months after Vaccination 2 (12 Months)
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: 30 days after vaccination 1
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: 30 days after vaccination 2
Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination Any Vaccination: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: 30 days after any vaccination
Stage1: Percentage of Participants With at Least 1 AE During the Stage 1 Vaccination Phase: Group 1 and Group 3
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1: Group 1 and Group 3
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
Time frame: 30 minutes after Vaccination 1
Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2: Group 1 and Group 3
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
Time frame: 30 minutes after Vaccination 2
Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase: Group 1 and Group 3
Time frame: Stage 1 Vaccination Phase: From Vaccination 1 through 1 month after Vaccination 2 (7 Months)
The study had 2 stages: 1 and 2. Study was conducted at 68 sites in Stage 1, with 39 of those sites participating in Stage 2. Participants were randomized as ACWY-naive and ACWY-experienced (received 1 prior dose of a vaccine containing 1 or more ACWY groups greater than or equal to \[\>=\] 4 years prior to randomization).
| Milestone | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Started | 272 | 537 | 272 | 529 |
| Vaccination 1 at month 0 | 272 | 534 | 271 | 523 |
| Vaccination 2 at month 6 | 242 | 469 | 244 | 477 |
| Completed | 233 | 462 | 232 | 463 |
| Not completed | 39 | 75 | 40 | 66 |
| Withdrew: Adverse event | 1 | 2 | 2 | 1 |
| Withdrew: Death | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 17 | 24 | 21 | 38 |
| Withdrew: No longer met eligibility criteria | 1 | 6 | 2 | 5 |
| Withdrew: Other | 0 | 2 | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 | 0 | 0 |
| Withdrew: Pregnancy | 0 | 4 | 2 | 4 |
| Withdrew: Protocol violation | 1 | 1 | 2 | 1 |
| Withdrew: Withdrawal by parent/guardian | 2 | 10 | 2 | 1 |
| Withdrew: Withdrawal by subject | 16 | 22 | 7 | 10 |
| Withdrew: Randomized but not vaccinated | 0 | 3 | 1 | 6 |
| Milestone | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Started | 114 | 65 | 101 | 73 |
| Antibody persistence: blood draw month18 | 114 | 63 | 53 | 23 |
| Antibody persistence: blood draw month 30 | 104 | 61 | 96 | 71 |
| Antibody persistence: blood draw month 42 | 97 | 55 | 97 | 68 |
| Received booster vaccination | 67 | 40 | 77 | 58 |
| Completed | 67 | 38 | 77 | 58 |
| Not completed | 47 | 27 | 24 | 15 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawn before booster vaccination | 46 | 24 | 24 | 15 |
| Withdrew: Did not receive booster vaccination | 1 | 1 | 0 | 0 |
Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome. Analysis for this outcome measure was planned for combined Group 2 and 4.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants Achieving Serum Bactericidal Assay Using Human Complement (hSBA) Titer Level >= Lower Limit of Quantitation (LLOQ) for All 4 Primary Test Strains Combined 1 Month After Vaccination 2 (Group 2 and 4 Combined) | 74.3 (71.2 to 77.3) |
The 4-fold increase: a) participants with baseline hSBA titer below limit of detection (LOD or an hSBA titer \<1:4), response was defined as hSBA titer \>=1:16 or LLOQ (whichever titer is higher); b) Participants with baseline hSBA titer \>= LOD and \< LLOQ, response was defined as hSBA titer \>= 4 times the LLOQ; c) participants with baseline hSBA titer \>= LLOQ, response was defined as hSBA titer \>=4 times baseline titer. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). Analysis for this outcome measure was planned for combined Group 2 and 4.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| PMB80 (A22) | 73.8 (70.6 to 76.7) |
| PMB2001 (A56) | 95.0 (93.3 to 96.4) |
| PMB2948 (B24) | 67.4 (64.1 to 70.6) |
| PMB2707 (B44) | 86.4 (83.9 to 88.6) |
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Redness: Any | 16.9 (14.6 to 19.3) |
| Redness: Mild | 6.8 (5.3 to 8.5) |
| Redness: Moderate | 8.0 (6.5 to 9.9) |
| Redness: Severe | 2.0 (1.2 to 3.1) |
| Swelling: Any | 17.0 (14.7 to 19.4) |
| Swelling: Mild | 9.8 (8.0 to 11.7) |
| Swelling: Moderate | 6.9 (5.4 to 8.6) |
| Swelling: Severe | 0.3 (0.1 to 0.8) |
| Pain at injection site: Any | 85.0 (82.6 to 87.1) |
| Pain at injection site: Mild | 41.2 (38.2 to 44.2) |
| Pain at injection site: Moderate | 39.1 (36.1 to 42.1) |
| Pain at injection site: Severe | 4.7 (3.5 to 6.2) |
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Redness: Any | 14.7 (12.5 to 17.2) |
| Redness: Mild | 5.2 (3.8 to 6.9) |
| Redness: Moderate | 8.4 (6.7 to 10.4) |
| Redness: Severe | 1.1 (0.5 to 2.0) |
| Swelling: Any | 14.3 (12.1 to 16.7) |
| Swelling: Mild | 6.4 (4.9 to 8.2) |
| Swelling: Moderate | 7.5 (5.9 to 9.4) |
| Swelling: Severe | 0.3 (0.1 to 1.0) |
| Pain at injection site: Any | 82.2 (79.5 to 84.6) |
| Pain at injection site: Mild | 38.9 (35.7 to 42.1) |
| Pain at injection site: Moderate | 37.9 (34.7 to 41.1) |
| Pain at injection site: Severe | 5.4 (4.0 to 7.1) |
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Fever: >= 38.0 degree C | 6.7 (5.3 to 8.4) |
| Fever: 38.0 to 38.4 degree C | 4.0 (2.9 to 5.4) |
| Fever: 38.5 to 38.9 degree C | 2.1 (1.3 to 3.2) |
| Fever: 39.0 to 40.0 degree C | 0.6 (0.2 to 1.2) |
| Fever: > 40.0 degree C | 0.0 (0.0 to 0.4) |
| Fatigue: Any | 51.9 (48.8 to 55.0) |
| Fatigue: Mild | 25.4 (22.8 to 28.1) |
| Fatigue: Moderate | 23.7 (21.1 to 26.4) |
| Fatigue: Severe | 2.9 (1.9 to 4.1) |
| Headache: Any | 46.5 (43.4 to 49.5) |
| Headache: Mild | 25.1 (22.5 to 27.8) |
| Headache: Moderate | 19.0 (16.6 to 21.5) |
| Headache: Severe | 2.4 (1.6 to 3.5) |
| Chills: Any | 18.5 (16.2 to 21.0) |
| Chills: Mild | 11.5 (9.6 to 13.6) |
| Chills: Moderate | 5.7 (4.4 to 7.3) |
| Chills: Severe | 1.2 (0.7 to 2.1) |
| Vomiting: Any | 3.7 (2.7 to 5.1) |
| Vomiting: Mild | 2.9 (1.9 to 4.1) |
| Vomiting: Moderate | 0.9 (0.4 to 1.6) |
| Vomiting: severe | 0.0 (0.0 to 0.4) |
| Diarrhea: Any | 14.1 (12.0 to 16.3) |
| Diarrhea: Mild | 10.7 (8.9 to 12.8) |
| Diarrhea: Moderate | 3.3 (2.3 to 4.5) |
| Diarrhea: Severe | 0.1 (0.0 to 0.5) |
| Muscle pain: Any | 28.4 (25.7 to 31.3) |
| Muscle pain: Mild | 15.8 (13.6 to 18.2) |
| Muscle pain: Moderate | 11.6 (9.7 to 13.7) |
| Muscle pain: Severe | 1.1 (0.5 to 1.9) |
| Joint pain: Any | 19.6 (17.3 to 22.2) |
| Joint pain: Mild | 10.2 (8.5 to 12.3) |
| Joint pain: Moderate | 8.6 (7.0 to 10.5) |
| Joint pain: Severe | 0.8 (0.3 to 1.5) |
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain other than muscle pain at the injection site, and joint pain were recorded by using an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Fever: >= 38.0 degree C | 3.2 (2.2 to 4.6) |
| Fever: 38.0 to 38.4 degree C | 1.9 (1.1 to 3.0) |
| Fever: 38.5 to 38.9 degree C | 0.7 (0.2 to 1.4) |
| Fever: 39.0 to 40.0 degree C | 0.7 (0.2 to 1.4) |
| Fever: > 40.0 degree C | 0.0 (0.0 to 0.4) |
| Fatigue: Any | 45.2 (41.9 to 48.5) |
| Fatigue: Mild | 23.0 (20.3 to 25.9) |
| Fatigue: Moderate | 19.2 (16.6 to 21.9) |
| Fatigue: Severe | 3.0 (2.0 to 4.3) |
| Headache: Any | 41.6 (38.4 to 44.9) |
| Headache: Mild | 23.1 (20.4 to 26.0) |
| Headache: Moderate | 16.5 (14.1 to 19.1) |
| Headache: Severe | 2.0 (1.2 to 3.1) |
| Chills: Any | 18.5 (16.0 to 21.2) |
| Chills: Mild | 11.6 (9.6 to 13.9) |
| Chills: Moderate | 6.2 (4.7 to 8.0) |
| Chills: Severe | 0.7 (0.2 to 1.4) |
| Vomiting: Any | 2.8 (1.8 to 4.1) |
| Vomiting: Mild | 2.0 (1.2 to 3.1) |
| Vomiting: Moderate | 0.8 (0.3 to 1.6) |
| Vomiting: Severe | 0.0 (0.0 to 0.4) |
| Diarrhea: Any | 10.6 (8.7 to 12.8) |
| Diarrhea: Mild | 7.6 (6.0 to 9.6) |
| Diarrhea: Moderate | 2.5 (1.6 to 3.8) |
| Diarrhea: Severe | 0.4 (0.1 to 1.1) |
| Muscle pain: Any | 21.4 (18.7 to 24.2) |
| Muscle pain: Mild | 11.5 (9.5 to 13.8) |
| Muscle pain: Moderate | 7.8 (6.1 to 9.7) |
| Muscle pain: Severe | 2.1 (1.3 to 3.3) |
| Joint pain: Any | 18.7 (16.2 to 21.4) |
| Joint pain: Mild | 11.2 (9.2 to 13.4) |
| Joint pain: Moderate | 6.5 (5.0 to 8.3) |
| Joint pain: Severe | 1.0 (0.5 to 1.9) |
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 1 (Group 2 and 4 Combined) | 18.6 (16.3 to 21.1) |
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Vaccination 2 (Group 2 and 4 Combined) | 14.4 (12.2 to 16.9) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined) | 0.0 (0.0 to 0.3) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Serious Adverse Event (SAE) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined) | 0.0 (0.0 to 0.4) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination (Group 2 and 4 Combined) | 0.0 (0.0 to 0.3) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined) | 0.8 (0.3 to 1.5) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined) | 0.5 (0.2 to 1.2) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1 (Group 2 and 4 Combined) | 1.3 (0.7 to 2.2) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined) | 6.3 (4.9 to 8.0) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined) | 8.8 (7.0 to 10.8) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined) | 13.3 (11.3 to 15.5) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined) | 26.7 (24.0 to 29.5) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase (Group 2 and 4 Combined) | 16.6 (14.3 to 19.2) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1 (Group 2 and 4 Combined) | 33.7 (30.8 to 36.6) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 1 (Group 2 and 4 Combined) | 0.3 (0.1 to 0.8) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Vaccination 2 (Group 2 and 4 Combined) | 0.2 (0.0 to 0.8) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Within 30 Days After Any Vaccination (Group 2 and 4 Combined) | 0.5 (0.2 to 1.1) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Vaccination Phase (Group 2 and 4 Combined) | 0.8 (0.3 to 1.5) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) During the Stage 1 Follow-up Phase (Group 2 and 4 Combined) | 0.3 (0.1 to 0.9) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Newly Diagnosed Chronic Medical Condition (NDCMC) Throughout the Stage 1 (Group 2 and 4) | 0.9 (0.5 to 1.7) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1 (Group 2 and 4 Combined) | 13.8 (11.8 to 16.0) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2 (Group 2 and 4 Combined) | 14.7 (12.5 to 17.1) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Any Vaccination (Group 2 and 4 Combined) | 24.1 (21.6 to 26.8) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 AE During Vaccination Phase (Group 2 and 4 Combined) | 40.7 (37.7 to 43.7) |
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1 (Group 2 and 4 Combined) | 0.9 (0.4 to 1.6) |
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2 (Group 2 and 4 Combined) | 0.3 (0.1 to 0.9) |
| Participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase (Group 2 and 4 Combined) | 171 |
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Redness: Any | 13.6 (6.0 to 25.0) | 28.6 (14.6 to 46.3) | 21.6 (12.9 to 32.7) | 25.5 (14.7 to 39.0) |
| Redness: Mild | 5.1 (1.1 to 14.1) | 11.4 (3.2 to 26.7) | 9.5 (3.9 to 18.5) | 14.5 (6.5 to 26.7) |
| Redness: Moderate | 3.4 (0.4 to 11.7) | 11.4 (3.2 to 26.7) | 8.1 (3.0 to 16.8) | 9.1 (3.0 to 20.0) |
| Redness: Severe | 5.1 (1.1 to 14.1) | 5.7 (0.7 to 19.2) | 4.1 (0.8 to 11.4) | 1.8 (0.0 to 9.7) |
| Swelling: Any | 18.6 (9.7 to 30.9) | 25.7 (12.5 to 43.3) | 18.9 (10.7 to 29.7) | 18.2 (9.1 to 30.9) |
| Swelling: Mild | 10.2 (3.8 to 20.8) | 11.4 (3.2 to 26.7) | 6.8 (2.2 to 15.1) | 9.1 (3.0 to 20.0) |
| Swelling: Moderate | 8.5 (2.8 to 18.7) | 11.4 (3.2 to 26.7) | 12.2 (5.7 to 21.8) | 7.3 (2.0 to 17.6) |
| Swelling: Severe | 0.0 (0.0 to 6.1) | 2.9 (0.1 to 14.9) | 0.0 (0.0 to 4.9) | 1.8 (0.0 to 9.7) |
| Pain at injection site: Any | 79.3 (66.6 to 88.8) | 85.7 (69.7 to 95.2) | 85.1 (75.0 to 92.3) | 85.5 (73.3 to 93.5) |
| Pain at injection site: Mild | 41.4 (28.6 to 55.1) | 25.7 (12.5 to 43.3) | 36.5 (25.6 to 48.5) | 47.3 (33.7 to 61.2) |
| Pain at injection site: Moderate | 36.2 (24.0 to 49.9) | 45.7 (28.8 to 63.4) | 47.3 (35.6 to 59.3) | 38.2 (25.4 to 52.3) |
| Pain at injection site: Severe | 1.7 (0.0 to 9.2) | 14.3 (4.8 to 30.3) | 1.4 (0.0 to 7.3) | 0.0 (0.0 to 6.5) |
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree Celsius (C) and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Fever: >= 38.0 degree C | 5.0 (1.0 to 13.9) | 2.6 (0.1 to 13.5) | 0.0 (0.0 to 4.7) | 1.8 (0.0 to 9.6) |
| Fever: 38.0 to 38.4 degree C | 1.7 (0.0 to 8.9) | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 4.7) | 1.8 (0.0 to 9.6) |
| Fever: 38.4 to 38.9 degree C | 0.0 (0.0 to 6.0) | 2.6 (0.1 to 13.5) | 0.0 (0.0 to 4.7) | 0.0 (0.0 to 6.4) |
| Fever: 38.9 to 40.0 degree C | 3.3 (0.4 to 11.5) | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 4.7) | 0.0 (0.0 to 6.4) |
| Fever: > 40.0 degree C | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 4.7) | 0.0 (0.0 to 6.4) |
| Fatigue: Any | 46.7 (33.7 to 60.0) | 61.5 (44.6 to 76.6) | 61.8 (50.0 to 72.8) | 66.1 (52.2 to 78.2) |
| Fatigue: Mild | 25.0 (14.7 to 37.9) | 25.6 (13.0 to 42.1) | 50.0 (38.3 to 61.7) | 37.5 (24.9 to 51.5) |
| Fatigue: Moderate | 21.7 (12.1 to 34.2) | 30.8 (17.0 to 47.6) | 10.5 (4.7 to 19.7) | 23.2 (13.0 to 36.4) |
| Fatigue: Severe | 0.0 (0.0 to 6.0) | 5.1 (0.6 to 17.3) | 1.3 (0.0 to 7.1) | 5.4 (1.1 to 14.9) |
| Headache: Any | 36.7 (24.6 to 50.1) | 53.8 (37.2 to 69.9) | 46.1 (34.5 to 57.9) | 55.4 (41.5 to 68.7) |
| Headache: Mild | 25.0 (14.7 to 37.9) | 20.5 (9.3 to 36.5) | 34.2 (23.7 to 46.0) | 39.3 (26.5 to 53.2) |
| Headache: Moderate | 8.3 (2.8 to 18.4) | 28.2 (15.0 to 44.9) | 10.5 (4.7 to 19.7) | 14.3 (6.4 to 26.2) |
| Headache: Severe | 3.3 (0.4 to 11.5) | 5.1 (0.6 to 17.3) | 1.3 (0.0 to 7.1) | 1.8 (0.0 to 9.6) |
| Chills: Any | 10.0 (3.8 to 20.5) | 17.9 (7.5 to 33.5) | 18.4 (10.5 to 29.0) | 14.3 (6.4 to 26.2) |
| Chills: Mild | 10.0 (3.8 to 20.5) | 12.8 (4.3 to 27.4) | 15.8 (8.4 to 26.0) | 12.5 (5.2 to 24.1) |
| Chills: Moderate | 0.0 (0.0 to 6.0) | 5.1 (0.6 to 17.3) | 2.6 (0.3 to 9.2) | 0.0 (0.0 to 6.4) |
| Chills: Severe | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 4.7) | 1.8 (0.0 to 9.6) |
| Vomiting: Any | 3.3 (0.4 to 11.5) | 0.0 (0.0 to 9.0) | 2.6 (0.3 to 9.2) | 1.8 (0.0 to 9.6) |
| Vomiting: Mild | 1.7 (0.0 to 8.9) | 0.0 (0.0 to 9.0) | 1.3 (0.0 to 7.1) | 1.8 (0.0 to 9.6) |
| Vomiting: Moderate | 1.7 (0.0 to 8.9) | 0.0 (0.0 to 9.0) | 1.3 (0.0 to 7.1) | 0.0 (0.0 to 6.4) |
| Vomiting: severe | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 4.7) | 0.0 (0.0 to 6.4) |
| Diarrhea: Any | 5.0 (1.0 to 13.9) | 10.3 (2.9 to 24.2) | 9.2 (3.8 to 18.1) | 12.5 (5.2 to 24.1) |
| Diarrhea: Mild | 5.0 (1.0 to 13.9) | 7.7 (1.6 to 20.9) | 7.9 (3.0 to 16.4) | 7.1 (2.0 to 17.3) |
| Diarrhea: Moderate | 0.0 (0.0 to 6.0) | 2.6 (0.1 to 13.5) | 1.3 (0.0 to 7.1) | 5.4 (1.1 to 14.9) |
| Diarrhea: Severe | 0.0 (0.0 to 6.0) | 0.0 (0.0 to 9.0) | 0.0 (0.0 to 4.7) | 0.0 (0.0 to 6.4) |
| Muscle Pain: Any | 18.3 (9.5 to 30.4) | 30.8 (17.0 to 47.6) | 31.6 (21.4 to 43.3) | 23.2 (13.0 to 36.4) |
| Muscle pain: Mild | 13.3 (5.9 to 24.6) | 10.3 (2.9 to 24.2) | 22.4 (13.6 to 33.4) | 19.6 (10.2 to 32.4) |
| Muscle pain: Moderate | 5.0 (1.0 to 13.9) | 12.8 (4.3 to 27.4) | 7.9 (3.0 to 16.4) | 3.6 (0.4 to 12.3) |
| Muscle pain: Severe | 0.0 (0.0 to 6.0) | 7.7 (1.6 to 20.9) | 1.3 (0.0 to 7.1) | 0.0 (0.0 to 6.4) |
| Joint Pain: Any | 18.3 (9.5 to 30.4) | 25.6 (13.0 to 42.1) | 21.1 (12.5 to 31.9) | 16.1 (7.6 to 28.3) |
| Joint pain: Mild | 15.0 (7.1 to 26.6) | 12.8 (4.3 to 27.4) | 11.8 (5.6 to 21.3) | 12.5 (5.2 to 24.1) |
| Joint pain: Moderate | 3.3 (0.4 to 11.5) | 10.3 (2.9 to 24.2) | 9.2 (3.8 to 18.1) | 3.6 (0.4 to 12.3) |
| Joint pain: Severe | 0.0 (0.0 to 6.0) | 2.6 (0.1 to 13.5) | 0.0 (0.0 to 4.7) | 0.0 (0.0 to 6.4) |
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With Antipyretic Medication Use Within 7 Days After Booster Vaccination: Group 1 Through Group 4 | 16.7 (8.3 to 28.5) | 20.5 (9.3 to 36.5) | 13.2 (6.5 to 22.9) | 10.7 (4.0 to 21.9) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was included in results of Group 4.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 SAE During Booster Vaccination Phase: Group 1 Through Group 4 | 0.0 (0.0 to 5.4) | 0.0 (0.0 to 8.8) | 0.0 (0.0 to 4.7) | 1.8 (0.0 to 9.6) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 SAE During the Booster Follow-up Phase: Group 1 Through Group 4 | 0.0 (0.0 to 5.4) | 0.0 (0.0 to 9.3) | 2.6 (0.3 to 9.1) | 0.0 (0.0 to 6.4) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. SAE of "pregnancy" for one participant during the booster vaccination phase was recorded erroneously and hence it was reported in result of outcome measure 37 for Group 4. Subsequently correction was made by the trial site and not included in subsequent phase/results. Hence, that 1 participant is not included in results of Group 4 here.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 SAE Throughout Booster Phase: Group 1 Through Group 4 | 0.0 (0.0 to 5.4) | 0.0 (0.0 to 8.8) | 2.6 (0.3 to 9.1) | 0.0 (0.0 to 6.4) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 Medically Attended AE During Booster Vaccination Phase: Group 1 Through Group 4 | 9.0 (3.4 to 18.5) | 5.0 (0.6 to 16.9) | 2.6 (0.3 to 9.1) | 7.1 (2.0 to 17.3) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 Medically Attended AE During the Booster Follow-up Phase: Group 1 Through Group 4 | 3.0 (0.4 to 10.4) | 13.2 (4.4 to 28.1) | 6.5 (2.1 to 14.5) | 7.1 (2.0 to 17.3) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 Medically Attended AE Throughout Booster Phase: Group 1 Through Group 4 | 10.4 (4.3 to 20.3) | 15.0 (5.7 to 29.8) | 7.8 (2.9 to 16.2) | 14.3 (6.4 to 26.2) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 NDCMC During Booster Vaccination Phase: Group 1 Through Group 4 | 0.0 (0.0 to 5.4) | 0.0 (0.0 to 8.8) | 0.0 (0.0 to 4.7) | 0.0 (0.0 to 6.4) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 NDCMC During the Booster Follow-up Phase: Group 1 Through Group 4 | 0.0 (0.0 to 5.4) | 0.0 (0.0 to 9.3) | 2.6 (0.3 to 9.1) | 0.0 (0.0 to 6.4) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 NDCMC Throughout Booster Phase: Group 1 Through Group 4 | 0.0 (0.0 to 5.4) | 0.0 (0.0 to 8.8) | 2.6 (0.3 to 9.1) | 0.0 (0.0 to 6.4) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 AE During Booster Vaccination Phase: Group 1 Through Group 4 | 13.4 (6.3 to 24.0) | 10.0 (2.8 to 23.7) | 10.4 (4.6 to 19.4) | 17.9 (8.9 to 30.4) |
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Percentage of Participants With at Least 1 Immediate AE After Booster Vaccination: Group 1 Through Group 4 | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) | 0.0 (0.0 to 0.0) |
| Participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| Stage2: Number of Participants Who Missed School/Work Due to AE After Booster Vaccination: Group 1 Through Group 4 | 3 | 0 | 3 | 2 |
Percentage of participants who achieved an hSBA titer \>= LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| PMB80 (A22) 1 month after Vaccination 2 | 91.0 (88.8 to 92.8) |
| PMB2001 (A56) 1 month after Vaccination 2 | 99.4 (98.6 to 99.8) |
| PMB2948 (B24) 1 month after Vaccination 2 | 79.3 (76.4 to 82.0) |
| PMB2707 (B44) 1 month after Vaccination 2 | 94.5 (92.7 to 95.9) |
Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for all 4 primary MenB test strains was reported in this outcome measure. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| PMB80 (A22) 1 Month after Vacc 2 >=1:4 | 91.7 (89.6 to 93.4) |
| PMB80 (A22) 1 Month after Vacc 2 >=1:8 | 91.5 (89.5 to 93.3) |
| PMB80 (A22) 1 Month after Vacc 2 >=1:16 | 91.0 (88.8 to 92.8) |
| PMB80 (A22) 1 Month after Vacc 2 >=1:32 | 80.2 (77.3 to 82.8) |
| PMB80 (A22) 1 Month after Vacc 2 >=1:64 | 54.9 (51.5 to 58.3) |
| PMB80 (A22) 1 Month after Vacc 2 >=1:128 | 27.3 (24.4 to 30.5) |
| PMB2001 (A56) 1 Month after Vacc 2 >=1:4 | 99.5 (98.8 to 99.9) |
| PMB2001 (A56) 1 Month after Vacc 2 >=1:8 | 99.4 (98.6 to 99.8) |
| PMB2001 (A56) 1 Month after Vacc 2 >=1:16 | 99.1 (98.2 to 99.6) |
| PMB2001 (A56) 1 Month after Vacc 2 >=1:32 | 97.0 (95.6 to 98.0) |
| PMB2001 (A56) 1 Month after Vacc 2 >=1:64 | 87.7 (85.3 to 89.8) |
| PMB2001 (A56) 1 Month after Vacc 2 >=1:128 | 69.2 (66.0 to 72.3) |
| PMB2948 (B24) 1 Month after Vacc 2 >=1:4 | 81.2 (78.4 to 83.8) |
| PMB2948 (B24) 1 Month after Vacc 2 >=1:8 | 79.3 (76.4 to 82.0) |
| PMB2948 (B24) 1 Month after Vacc 2 >=1:16 | 74.0 (70.9 to 76.9) |
| PMB2948 (B24) 1 Month after Vacc 2 >=1:32 | 47.9 (44.4 to 51.3) |
| PMB2948 (B24) 1 Month after Vacc 2 >=1:64 | 24.9 (22.1 to 28.0) |
| PMB2948 (B24) 1 Month after Vacc 2 >=1:128 | 9.6 (7.7 to 11.8) |
| PMB2707 (B44) 1 Month after Vacc 2 >=1:4 | 96.2 (94.7 to 97.4) |
| PMB2707 (B44) 1 Month after Vacc 2 >=1:8 | 94.5 (92.7 to 95.9) |
| PMB2707 (B44) 1 Month after Vacc 2 >=1:16 | 89.0 (86.7 to 91.0) |
| PMB2707 (B44) 1 Month after Vacc 2 >=1:32 | 68.6 (65.3 to 71.7) |
| PMB2707 (B44) 1 Month after Vacc 2 >=1:64 | 41.0 (37.7 to 44.4) |
| PMB2707 (B44) 1 Month after Vacc 2 >=1:128 | 19.2 (16.6 to 22.0) |
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5 \* LLOQ for analysis. Four primary MenB test strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44).
| Titers | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| PMB80 (A22) 1 month after Vacc 2 | 49.3 (46.2 to 52.6) |
| PMB2001 (A56) 1 month after Vacc 2 | 139.5 (130.6 to 149.1) |
| PMB2948 (B24) 1 month after Vacc 2 | 21.2 (19.6 to 22.9) |
| PMB2707 (B44) 1 month after Vacc 2 | 37.8 (35.1 to 40.8) |
Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for 10 Secondary MenB test strains combined (LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16) was reported in this outcome measure.
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| PMB3175 (A29) 1 month after Vacc 2 | 95.2 (90.7 to 97.9) |
| PMB3010 (A06) 1 month after Vacc 2 | 89.3 (83.4 to 93.6) |
| PMB824 (A12) 1 month after Vacc 2 | 83.4 (76.7 to 88.9) |
| PMB3040 (A07) 1 month after Vacc 2 | 96.8 (92.7 to 99.0) |
| PMB1672 (A15) 1 month after Vacc 2 | 89.1 (83.3 to 93.4) |
| PMB1989 (A19) 1 month after Vacc 2 | 90.4 (84.9 to 94.4) |
| PMB648 (B16) 1 month after Vacc 2 | 77.4 (70.3 to 83.6) |
| PMB866 (B09) 1 month after Vacc 2 | 71.1 (63.6 to 77.8) |
| PMB1256 (B03) 1 month after Vacc 2 | 74.4 (67.0 to 80.9) |
| PMB431 (B15) 1 month after Vacc 2 | 85.0 (78.7 to 90.1) |
Percentage of participants who achieved an hSBA titer \>= 1:4, \>= 1:8, \>= 1:16, \>= 1:32, \>= 1:64, \>= 1:128 for each of the 10 secondary MenB test strains was reported in this outcome measure. 10 secondary MenB test strains were PMB3175 (A29), PMB3010 (A06), PMB824 (A12), PMB3040 (A07), PMB1672 (A15), PMB1989 (A19), PMB648 (B16), PMB866 (B09), PMB1256 (B03) and PMB431 (B15).
| Percentage of participants | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| PMB3175 (A29) 1 Month after Vacc 2 >=1:4 | 95.8 (91.5 to 98.3) |
| PMB3175 (A29) 1 Month after Vacc 2 >=1:8 | 95.2 (90.7 to 97.9) |
| PMB3175 (A29) 1 Month after Vacc 2 >=1:16 | 92.2 (87.0 to 95.8) |
| PMB3175 (A29) 1 Month after Vacc 2 >=1:32 | 71.7 (64.2 to 78.4) |
| PMB3175 (A29) 1 Month after Vacc 2 >=1:64 | 38.0 (30.5 to 45.8) |
| PMB3175 (A29) 1 Month after Vacc 2 >=1:128 | 13.9 (9.0 to 20.1) |
| PMB3010 (A06) 1 Month after Vacc 2 >=1:4 | 89.9 (84.2 to 94.1) |
| PMB3010 (A06) 1 Month after Vacc 2 >=1:8 | 89.3 (83.4 to 93.6) |
| PMB3010 (A06) 1 Month after Vacc 2 >=1:16 | 89.3 (83.4 to 93.6) |
| PMB3010 (A06) 1 Month after Vacc 2 >=1:32 | 79.9 (72.8 to 85.8) |
| PMB3010 (A06) 1 Month after Vacc 2 >=1:64 | 54.7 (46.6 to 62.6) |
| PMB3010 (A06) 1 Month after Vacc 2 >=1:128 | 22.0 (15.8 to 29.3) |
| PMB824 (A12) 1 Month after Vacc 2 >=1:4 | 89.2 (83.2 to 93.6) |
| PMB824 (A12) 1 Month after Vacc 2 >=1:8 | 87.9 (81.7 to 92.6) |
| PMB824 (A12) 1 Month after Vacc 2 >=1:16 | 83.4 (76.7 to 88.9) |
| PMB824 (A12) 1 Month after Vacc 2 >=1:32 | 52.9 (44.8 to 60.9) |
| PMB824 (A12) 1 Month after Vacc 2 >=1:64 | 18.5 (12.7 to 25.4) |
| PMB824 (A12) 1 Month after Vacc 2 >=1:128 | 1.3 (0.2 to 4.5) |
| PMB3040 (A07) 1 Month after Vacc 2 >=1:4 | 96.8 (92.7 to 99.0) |
| PMB3040 (A07) 1 Month after Vacc 2 >=1:8 | 96.8 (92.7 to 99.0) |
| PMB3040 (A07) 1 Month after Vacc 2 >=1:16 | 96.8 (92.7 to 99.0) |
| PMB3040 (A07) 1 Month after Vacc 2 >=1:32 | 94.3 (89.4 to 97.3) |
| PMB3040 (A07) 1 Month after Vacc 2 >=1:64 | 68.8 (60.9 to 75.9) |
| PMB3040 (A07) 1 Month after Vacc 2 >=1:128 | 31.2 (24.1 to 39.1) |
| PMB1672 (A15) 1 Month after Vacc 2 >=1:4 | 89.1 (83.3 to 93.4) |
| PMB1672 (A15) 1 Month after Vacc 2 >=1:8 | 89.1 (83.3 to 93.4) |
| PMB1672 (A15) 1 Month after Vacc 2 >=1:16 | 87.3 (81.2 to 91.9) |
| PMB1672 (A15) (n=165) 1 Month after Vacc 2 >=1:32 | 69.7 (62.1 to 76.6) |
| PMB1672 (A15) 1 Month after Vacc 2 >=1:64 | 30.3 (23.4 to 37.9) |
| PMB1672 (A15) 1 Month after Vacc 2 >=1:128 | 5.5 (2.5 to 10.1) |
| PMB1989 (A19) 1 Month after Vacc 2 >=1:4 | 92.2 (87.1 to 95.8) |
| PMB1989 (A19) 1 Month after Vacc 2 >=1:8 | 92.2 (87.1 to 95.8) |
| PMB1989 (A19) 1 Month after Vacc 2 >=1:16 | 90.4 (84.9 to 94.4) |
| PMB1989 (A19) 1 Month after Vacc 2 >=1:32 | 84.4 (78.0 to 89.6) |
| PMB1989 (A19) 1 Month after Vacc 2 >=1:64 | 61.1 (53.2 to 68.5) |
| PMB1989 (A19) 1 Month after Vacc 2 >=1:128 | 28.7 (22.0 to 36.2) |
| PMB648 (B16) 1 Month after Vacc 2 >=1:4 | 79.3 (72.3 to 85.2) |
| PMB648 (B16) 1 Month after Vacc 2 >=1:8 | 77.4 (70.3 to 83.6) |
| PMB648 (B16) 1 Month after Vacc 2 >=1:16 | 73.8 (66.4 to 80.3) |
| PMB648 (B16) 1 Month after Vacc 2 >=1:32 | 51.2 (43.3 to 59.1) |
| PMB648 (B16) 1 Month after Vacc 2 >=1:64 | 28.7 (21.9 to 36.2) |
| PMB648 (B16) 1 Month after Vacc 2 >=1:128 | 6.1 (3.0 to 10.9) |
| PMB866 (B09) 1 Month after Vacc 2 >=1:4 | 74.7 (67.4 to 81.1) |
| PMB866 (B09) 1 Month after Vacc 2 >=1:8 | 71.1 (63.6 to 77.8) |
| PMB866 (B09) 1 Month after Vacc 2 >=1:16 | 63.3 (55.4 to 70.6) |
| PMB866 (B09) 1 Month after Vacc 2 >=1:32 | 34.3 (27.2 to 42.1) |
| PMB866 (B09) 1 Month after Vacc 2 >=1:64 | 8.4 (4.7 to 13.7) |
| PMB866 (B09) 1 Month after Vacc 2 >=1:128 | 2.4 (0.7 to 6.1) |
| PMB1256 (B03) 1 Month after Vacc 2 >=1:4 | 77.4 (70.3 to 83.6) |
| PMB1256 (B03) 1 Month after Vacc 2 >=1:8 | 74.4 (67.0 to 80.9) |
| PMB1256 (B03) 1 Month after Vacc 2 >=1:16 | 64.0 (56.2 to 71.4) |
| PMB1256 (B03) 1 Month after Vacc 2 >=1:32 | 42.1 (34.4 to 50.0) |
| PMB1256 (B03) 1 Month after Vacc 2 >=1:64 | 23.2 (16.9 to 30.4) |
| PMB1256 (B03) 1 Month after Vacc 2 >=1:128 | 7.3 (3.8 to 12.4) |
| PMB431 (B15) 1 Month after Vacc 2 >=1:4 | 87.4 (81.4 to 92.0) |
| PMB431 (B15) 1 Month after Vacc 2 >=1:8 | 85.0 (78.7 to 90.1) |
| PMB431 (B15) 1 Month after Vacc 2 >=1:16 | 72.5 (65.0 to 79.1) |
| PMB431 (B15) 1 Month after Vacc 2 >=1:32 | 36.5 (29.2 to 44.3) |
| PMB431 (B15) 1 Month after Vacc 2 >=1:64 | 15.0 (9.9 to 21.3) |
| PMB431 (B15) 1 Month after Vacc 2 >=1:128 | 2.4 (0.7 to 6.0) |
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:16 for A06, A12, and A19; 1:8 for A07, A15, A29, B03, B09, B15, and B16. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
| Titers | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|
| PMB3175 (A29) 1 month after Vacc 2 | 35.7 (30.9 to 41.2) |
| PMB3010 (A06) 1 month after Vacc 2 | 46.0 (39.7 to 53.1) |
| PMB824 (A12) 1 month after Vacc 2 | 23.7 (21.2 to 26.5) |
| PMB3040 (A07) 1 month after Vacc 2 | 60.7 (53.6 to 68.8) |
| PMB1672 (A15) 1 month after Vacc 2 | 28.4 (24.7 to 32.7) |
| PMB1989 (A19) 1 month after Vacc 2 | 53.5 (46.3 to 61.9) |
| PMB648 (B16) 1 month after Vacc 2 | 20.8 (17.5 to 24.6) |
| PMB866 (B09) 1 month after Vacc 2 | 13.9 (12.0 to 16.2) |
| PMB1256 (B03) 1 month after Vacc 2 | 17.7 (14.8 to 21.3) |
| PMB431 (B15) 1 month after Vacc 2 | 17.3 (15.1 to 19.8) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| MenA | 99.2 (97.3 to 99.9) | 98.4 (96.9 to 99.3) | 100.0 (98.3 to 100.0) | 99.3 (97.9 to 99.8) |
| MenC | 92.4 (88.5 to 95.3) | 88.6 (85.5 to 91.2) | 100.0 (98.6 to 100.0) | 99.4 (98.3 to 99.9) |
| MenW | 98.5 (96.2 to 99.6) | 95.5 (93.3 to 97.1) | 99.5 (97.5 to 100.0) | 99.5 (98.3 to 99.9) |
| MenY | 99.6 (97.9 to 100.0) | 96.9 (95.0 to 98.2) | 99.5 (97.5 to 100.0) | 99.8 (98.7 to 100.0) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| MenA >=1:4 | 99.6 (97.9 to 100.0) | 98.4 (96.9 to 99.3) | 100.0 (98.3 to 100.0) | 99.3 (97.9 to 99.8) |
| MenA >=1:8 | 99.2 (97.3 to 99.9) | 98.4 (96.9 to 99.3) | 100.0 (98.3 to 100.0) | 99.3 (97.9 to 99.8) |
| MenA >=1:16 | 98.5 (96.2 to 99.6) | 98.0 (96.4 to 99.1) | 100.0 (98.3 to 100.0) | 99.3 (97.9 to 99.8) |
| MenA >=1:32 | 97.7 (95.1 to 99.2) | 93.9 (91.5 to 95.8) | 99.5 (97.5 to 100.0) | 99.0 (97.5 to 99.7) |
| MenA >=1:64 | 90.9 (86.8 to 94.1) | 86.3 (83.0 to 89.1) | 99.1 (96.7 to 99.9) | 98.3 (96.5 to 99.3) |
| MenA >= 1:128 | 75.0 (69.3 to 80.1) | 71.2 (67.0 to 75.1) | 95.4 (91.7 to 97.8) | 96.4 (94.1 to 97.9) |
| MenC >=1:4 | 95.4 (92.1 to 97.6) | 93.3 (90.8 to 95.3) | 100.0 (98.6 to 100.0) | 99.4 (98.3 to 99.9) |
| MenC >=1:8 | 92.4 (88.5 to 95.3) | 88.6 (85.5 to 91.2) | 100.0 (98.6 to 100.0) | 99.4 (98.3 to 99.9) |
| MenC >=1:16 | 88.2 (83.6 to 91.8) | 80.9 (77.3 to 84.3) | 100.0 (98.6 to 100.0) | 99.2 (98.0 to 99.8) |
| MenC >=1:32 | 76.3 (70.7 to 81.3) | 67.8 (63.5 to 71.8) | 98.9 (96.7 to 99.8) | 98.2 (96.7 to 99.2) |
| MenC >=1:64 | 61.8 (55.7 to 67.7) | 55.0 (50.6 to 59.4) | 97.3 (94.6 to 98.9) | 97.2 (95.4 to 98.5) |
| MenC >=1:128 | 50.8 (44.5 to 57.0) | 45.6 (41.2 to 50.0) | 95.5 (92.2 to 97.6) | 94.1 (91.6 to 96.0) |
| MenW >=1:4 | 99.6 (97.9 to 100.0) | 97.7 (95.9 to 98.8) | 100.0 (98.3 to 100.0) | 99.5 (98.3 to 99.9) |
| MenW >=1:8 | 98.5 (96.2 to 99.6) | 95.5 (93.3 to 97.1) | 99.5 (97.5 to 100.0) | 99.5 (98.3 to 99.9) |
| MenW >=1:16 | 96.2 (93.1 to 98.2) | 89.3 (86.2 to 91.8) | 99.5 (97.5 to 100.0) | 99.3 (97.9 to 99.9) |
| MenW >=1:32 | 82.2 (77.0 to 86.6) | 75.0 (71.0 to 78.7) | 99.5 (97.5 to 100.0) | 98.1 (96.2 to 99.2) |
| MenW >=1:64 | 65.9 (59.8 to 71.6) | 56.1 (51.6 to 60.4) | 99.1 (96.7 to 99.9) | 96.6 (94.4 to 98.1) |
| MenW >=1:128 | 43.9 (37.9 to 50.2) | 38.1 (33.9 to 42.4) | 98.6 (96.0 to 99.7) | 94.0 (91.2 to 96.1) |
| MenY >=1:4 | 100.0 (98.6 to 100.0) | 99.2 (98.0 to 99.8) | 99.5 (97.5 to 100.0) | 100.0 (99.1 to 100.0) |
| MenY >=1:8 | 99.6 (97.9 to 100.0) | 96.9 (95.0 to 98.2) | 99.5 (97.5 to 100.0) | 99.8 (98.7 to 100.0) |
| MenY >=1:16 | 98.9 (96.7 to 99.8) | 92.9 (90.4 to 95.0) | 99.5 (97.5 to 100.0) | 99.3 (97.9 to 99.8) |
| MenY >=1:32 | 92.4 (88.5 to 95.3) | 82.4 (78.8 to 85.6) | 99.1 (96.7 to 99.9) | 99.0 (97.5 to 99.7) |
| MenY >=1:64 | 78.3 (72.9 to 83.2) | 66.9 (62.6 to 70.9) | 99.1 (96.7 to 99.9) | 97.1 (95.0 to 98.5) |
| MenY >=1:128 | 62.0 (55.8 to 67.9) | 48.6 (44.2 to 53.1) | 98.6 (96.0 to 99.7) | 94.9 (92.3 to 96.8) |
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
| Titers | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| MenA | 215.8 (184.6 to 252.4) | 203.2 (178.7 to 231.0) | 568.6 (492.9 to 656.0) | 916.1 (809.1 to 1037.3) |
| MenC | 111.5 (87.2 to 142.6) | 81.4 (68.1 to 97.4) | 814.9 (689.4 to 963.2) | 827.0 (722.5 to 946.6) |
| MenW | 98.4 (80.7 to 120.0) | 71.2 (61.5 to 82.4) | 1214.9 (1032.0 to 1430.1) | 1176.7 (1017.9 to 1360.2) |
| MenY | 141.9 (118.8 to 169.4) | 96.6 (83.9 to 111.2) | 1174.0 (990.3 to 1391.9) | 1000.2 (872.1 to 1147.1) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>= LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
| Percentage of participants | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|---|---|
| MenA | 98.4 (96.9 to 99.3) | 99.3 (97.9 to 99.8) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenC | 88.6 (85.5 to 91.2) | 99.4 (98.3 to 99.9) | 100.0 (98.4 to 100.0) | 99.6 (97.7 to 100.0) |
| MenW | 95.5 (93.3 to 97.1) | 99.5 (98.3 to 99.9) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenY | 96.9 (95.0 to 98.2) | 99.8 (98.7 to 100.0) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.
| Percentage of participants | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|---|---|
| MenA >=1:4 | 98.4 (96.9 to 99.3) | 99.3 (97.9 to 99.8) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenA >=1:8 | 98.4 (96.9 to 99.3) | 99.3 (97.9 to 99.8) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenA >=1:16 | 98.0 (96.4 to 99.1) | 99.3 (97.9 to 99.8) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenA >=1:32 | 93.9 (91.5 to 95.8) | 99.0 (97.5 to 99.7) | 97.8 (95.0 to 99.3) | 99.5 (97.1 to 100.0) |
| MenA >=1:64 | 86.3 (83.0 to 89.1) | 98.3 (96.5 to 99.3) | 92.2 (88.0 to 95.3) | 97.4 (94.0 to 99.1) |
| MenA >=1:128 | 71.2 (67.0 to 75.1) | 96.4 (94.1 to 97.9) | 69.4 (63.0 to 75.3) | 92.7 (88.0 to 95.9) |
| MenC >=1:4 | 93.3 (90.8 to 95.3) | 99.4 (98.3 to 99.9) | 100.0 (98.4 to 100.0) | 99.6 (97.7 to 100.0) |
| MenC >=1:8 | 88.6 (85.5 to 91.2) | 99.4 (98.3 to 99.9) | 100.0 (98.4 to 100.0) | 99.6 (97.7 to 100.0) |
| MenC >=1:16 | 80.9 (77.3 to 84.3) | 99.2 (98.0 to 99.8) | 99.6 (97.6 to 100.0) | 99.6 (97.7 to 100.0) |
| MenC >=1:32 | 67.8 (63.5 to 71.8) | 98.2 (96.7 to 99.2) | 97.4 (94.4 to 99.0) | 99.6 (97.7 to 100.0) |
| MenC >=1:64 | 55.0 (50.6 to 59.4) | 97.2 (95.4 to 98.5) | 90.9 (86.4 to 94.3) | 98.3 (95.7 to 99.5) |
| MenC >=1:128 | 45.6 (41.2 to 50.0) | 94.1 (91.6 to 96.0) | 78.8 (72.9 to 83.9) | 92.8 (88.8 to 95.8) |
| MenW >=1:4 | 97.7 (95.9 to 98.8) | 99.5 (98.3 to 99.9) | 100.0 (98.4 to 100.0) | 100.0 (98.1 to 100.0) |
| MenW >=1:8 | 95.5 (93.3 to 97.1) | 99.5 (98.3 to 99.9) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenW >=1:16 | 89.3 (86.2 to 91.8) | 99.3 (97.9 to 99.9) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenW >=1:32 | 75.0 (71.0 to 78.7) | 98.1 (96.2 to 99.2) | 99.6 (97.6 to 100.0) | 99.5 (97.1 to 100.0) |
| MenW >=1:64 | 56.1 (51.6 to 60.4) | 96.6 (94.4 to 98.1) | 97.0 (93.9 to 98.8) | 99.0 (96.3 to 99.9) |
| MenW >=1:128 | 38.1 (33.9 to 42.4) | 94.0 (91.2 to 96.1) | 89.7 (85.1 to 93.3) | 97.9 (94.7 to 99.4) |
| MenY >=1:4 | 99.2 (98.0 to 99.8) | 100.0 (99.1 to 100.0) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenY >=1:8 | 96.9 (95.0 to 98.2) | 99.8 (98.7 to 100.0) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenY >=1:16 | 92.9 (90.4 to 95.0) | 99.3 (97.9 to 99.8) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenY >=1:32 | 82.4 (78.8 to 85.6) | 99.0 (97.5 to 99.7) | 100.0 (98.4 to 100.0) | 99.5 (97.1 to 100.0) |
| MenY >=1:64 | 66.9 (62.6 to 70.9) | 97.1 (95.0 to 98.5) | 97.4 (94.5 to 99.0) | 99.5 (97.1 to 100.0) |
| MenY >=1:128 | 48.6 (44.2 to 53.1) | 94.9 (92.3 to 96.8) | 89.7 (85.1 to 93.3) | 95.3 (91.2 to 97.8) |
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
| Titers | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|---|---|
| MenA | 203.2 (178.7 to 231.0) | 916.1 (809.1 to 1037.3) | 151.3 (134.1 to 170.7) | 337.3 (291.7 to 390.0) |
| MenC | 81.4 (68.1 to 97.4) | 827.0 (722.5 to 946.6) | 229.1 (194.7 to 269.5) | 498.7 (429.1 to 579.6) |
| MenW | 71.2 (61.5 to 82.4) | 1176.7 (1017.9 to 1360.2) | 274.1 (242.7 to 309.7) | 570.9 (484.3 to 673.0) |
| MenY | 96.6 (83.9 to 111.2) | 1000.2 (872.1 to 1147.1) | 301.5 (266.6 to 341.0) | 558.6 (470.0 to 663.9) |
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
| Percentage of participants | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) 1 month after Vacc 2 | 91.0 (87.9 to 93.5) | 91.0 (88.8 to 92.8) |
| PMB2001 (A56) 1 month after Vacc 2 | 98.6 (97.0 to 99.5) | 99.4 (98.6 to 99.8) |
| PMB2948 (B24) 1 month after Vacc 2 | 84.3 (80.5 to 87.6) | 79.3 (76.4 to 82.0) |
| PMB2707 (B44) 1 month after Vacc 2 | 95.4 (93.0 to 97.2) | 94.5 (92.7 to 95.9) |
Percentage of participants who achieved an hSBA titer greater than or equal to LLOQ for all 4 primary MenB test strains combined (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
| Percentage of participants | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) | 75.8 (71.5 to 79.8) | 73.8 (70.6 to 76.7) |
| PMB2001 (A56) | 94.7 (92.1 to 96.7) | 95.0 (93.3 to 96.4) |
| PMB2948 (B24) | 76.1 (71.7 to 80.1) | 67.4 (64.1 to 70.6) |
| PMB2707 (B44) | 91.7 (88.6 to 94.1) | 86.4 (83.9 to 88.6) |
| Composite hSBA response | 79.9 (75.7 to 83.6) | 74.3 (71.2 to 77.3) |
Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for all 4 primary MenB test strains was reported in this outcome measure.
| Percentage of participants | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) >=1:4 | 91.9 (88.9 to 94.3) | 91.7 (89.6 to 93.4) |
| PMB80 (A22) >=1:8 | 91.7 (88.7 to 94.1) | 91.5 (89.5 to 93.3) |
| PMB80 (A22) >=1:16 | 91.0 (87.9 to 93.5) | 91.0 (88.8 to 92.8) |
| PMB80 (A22) >=1:32 | 82.4 (78.5 to 85.9) | 80.2 (77.3 to 82.8) |
| PMB80 (A22) >=1:64 | 58.0 (53.2 to 62.7) | 54.9 (51.5 to 58.3) |
| PMB80 (A22) >=1:128 | 27.9 (23.8 to 32.4) | 27.3 (24.4 to 30.5) |
| PMB2001 (A56) >=1:4 | 98.9 (97.3 to 99.6) | 99.5 (98.8 to 99.9) |
| PMB2001 (A56) >=1:8 | 98.6 (97.0 to 99.5) | 99.4 (98.6 to 99.8) |
| PMB2001 (A56) >=1:16 | 98.6 (97.0 to 99.5) | 99.1 (98.2 to 99.6) |
| PMB2001 (A56) >=1:32 | 96.8 (94.7 to 98.2) | 97.0 (95.6 to 98.0) |
| PMB2001 (A56) >=1:64 | 90.1 (86.9 to 92.8) | 87.7 (85.3 to 89.8) |
| PMB2001 (A56) >=1:128 | 74.0 (69.6 to 78.1) | 69.2 (66.0 to 72.3) |
| PMB2948 (B24) >=1:4 | 86.9 (83.3 to 89.9) | 81.2 (78.4 to 83.8) |
| PMB2948 (B24) >=1:8 | 84.3 (80.5 to 87.6) | 79.3 (76.4 to 82.0) |
| PMB2948 (B24) >=1:16 | 80.8 (76.7 to 84.4) | 74.0 (70.9 to 76.9) |
| PMB2948 (B24) >=1:32 | 58.5 (53.6 to 63.2) | 47.9 (44.4 to 51.3) |
| PMB2948 (B24) >=1:64 | 31.0 (26.6 to 35.6) | 24.9 (22.1 to 28.0) |
| PMB2948 (B24) >=1:128 | 13.4 (10.3 to 17.0) | 9.6 (7.7 to 11.8) |
| PMB2707 (B44) >=1:4 | 97.2 (95.2 to 98.6) | 96.2 (94.7 to 97.4) |
| PMB2707 (B44) >=1:8 | 95.4 (93.0 to 97.2) | 94.5 (92.7 to 95.9) |
| PMB2707 (B44) >=1:16 | 92.4 (89.5 to 94.7) | 89.0 (86.7 to 91.0) |
| PMB2707 (B44) >=1:32 | 72.9 (68.5 to 77.1) | 68.6 (65.3 to 71.7) |
| PMB2707 (B44) >=1:64 | 48.9 (44.1 to 53.7) | 41.0 (37.7 to 44.4) |
| PMB2707 (B44) >=1:128 | 22.0 (18.2 to 26.2) | 19.2 (16.6 to 22.0) |
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis.
| Titers | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) | 51.0 (46.7 to 55.7) | 49.3 (46.2 to 52.6) |
| PMB2001 (A56) | 152.3 (138.5 to 167.5) | 139.5 (130.6 to 149.1) |
| PMB2948 (B24) | 26.6 (23.9 to 29.7) | 21.2 (19.6 to 22.9) |
| PMB2707 (B44) | 43.3 (39.1 to 47.9) | 37.8 (35.1 to 40.8) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| MenA Before Vacc 1 | 15.9 (11.8 to 20.8) | 22.9 (19.4 to 26.7) | 53.9 (47.0 to 60.6) | 52.6 (47.7 to 57.5) |
| MenA Before Vacc 2 | 91.6 (87.3 to 94.8) | 86.2 (82.7 to 89.2) | 99.0 (96.4 to 99.9) | 98.4 (96.6 to 99.4) |
| MenC Before Vacc 1 | 38.6 (32.7 to 44.7) | 39.0 (34.8 to 43.3) | 59.5 (53.3 to 65.4) | 61.1 (56.7 to 65.3) |
| MenC Before Vacc 2 | 92.9 (88.9 to 95.8) | 76.5 (72.4 to 80.3) | 98.4 (95.8 to 99.5) | 98.3 (96.7 to 99.3) |
| MenW Before Vacc 1 | 32.1 (26.5 to 38.0) | 34.5 (30.5 to 38.8) | 61.9 (55.1 to 68.4) | 60.8 (55.9 to 65.5) |
| MenW Before Vacc 2 | 99.2 (97.0 to 99.9) | 91.0 (88.0 to 93.4) | 100.0 (98.2 to 100.0) | 99.0 (97.4 to 99.7) |
| MenY Before Vacc 1 | 54.0 (47.8 to 60.1) | 58.1 (53.8 to 62.4) | 79.9 (74.0 to 85.0) | 77.9 (73.6 to 81.8) |
| MenY Before Vacc 2 | 100.0 (98.5 to 100.0) | 97.2 (95.2 to 98.5) | 100.0 (98.2 to 100.0) | 99.5 (98.1 to 99.9) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=1:4, \>= :8, \>=1:16, \>=1:32, \>=1:64, \>=1:128 for ACWY test strains was reported in this outcome measure.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| MenA Before Vacc 1 >=1:4 | 26.3 (21.1 to 32.0) | 33.3 (29.3 to 37.5) | 64.4 (57.7 to 70.7) | 65.8 (61.0 to 70.3) |
| MenA Before Vacc 1 >=1:8 | 15.9 (11.8 to 20.8) | 22.9 (19.4 to 26.7) | 53.9 (47.0 to 60.6) | 52.6 (47.7 to 57.5) |
| MenA Before Vacc 1 >=1:16 | 14.4 (10.5 to 19.2) | 18.0 (14.8 to 21.5) | 40.2 (33.6 to 47.0) | 41.6 (36.9 to 46.5) |
| MenA Before Vacc 1 >=1:32 | 8.5 (5.5 to 12.5) | 10.6 (8.1 to 13.6) | 24.2 (18.7 to 30.4) | 22.0 (18.1 to 26.3) |
| MenA Before Vacc 1 >=1:64 | 5.2 (2.9 to 8.5) | 5.5 (3.7 to 7.8) | 12.8 (8.7 to 17.9) | 15.1 (11.8 to 18.9) |
| MenA Before Vacc 1 >=1:128 | 3.0 (1.3 to 5.8) | 4.0 (2.5 to 6.0) | 7.8 (4.6 to 12.1) | 6.2 (4.1 to 9.0) |
| MenA Before Vacc 2 >=1:4 | 93.3 (89.3 to 96.1) | 88.3 (85.1 to 91.1) | 99.0 (96.4 to 99.9) | 98.4 (96.6 to 99.4) |
| MenA Before Vacc 2 >=1:8 | 91.6 (87.3 to 94.8) | 86.2 (82.7 to 89.2) | 99.0 (96.4 to 99.9) | 98.4 (96.6 to 99.4) |
| MenA Before Vacc 2 >=1:16 | 87.4 (82.5 to 91.3) | 81.9 (78.0 to 85.3) | 98.0 (95.0 to 99.5) | 98.4 (96.6 to 99.4) |
| MenA Before Vacc 2 >=1:32 | 72.3 (66.1 to 77.9) | 66.3 (61.8 to 70.6) | 95.5 (91.6 to 97.9) | 96.1 (93.7 to 97.8) |
| MenA Before Vacc 2 >=1:64 | 44.5 (38.1 to 51.1) | 50.5 (45.9 to 55.2) | 85.0 (79.3 to 89.6) | 88.8 (85.3 to 91.8) |
| MenA Before Vacc 2 >=1:128 | 25.2 (19.8 to 31.2) | 33.5 (29.2 to 38.0) | 64.0 (56.9 to 70.6) | 75.3 (70.7 to 79.6) |
| MenC Before Vacc 1 >=1:4 | 63.7 (57.6 to 69.4) | 59.7 (55.4 to 63.9) | 76.1 (70.5 to 81.1) | 78.3 (74.4 to 81.8) |
| MenC Before Vacc 1 >=1:8 | 38.6 (32.7 to 44.7) | 39.0 (34.8 to 43.3) | 59.5 (53.3 to 65.4) | 61.1 (56.7 to 65.3) |
| MenC Before Vacc 1 >=1:16 | 24.3 (19.3 to 29.9) | 24.5 (20.9 to 28.4) | 42.0 (36.0 to 48.3) | 44.4 (40.1 to 48.9) |
| MenC Before Vacc 1 >=1:32 | 12.0 (8.3 to 16.5) | 12.5 (9.8 to 15.7) | 26.9 (21.6 to 32.7) | 29.7 (25.8 to 33.9) |
| MenC Before Vacc 1 >=1:64 | 5.2 (2.9 to 8.6) | 6.8 (4.8 to 9.3) | 15.9 (11.7 to 20.9) | 18.2 (14.9 to 21.8) |
| MenC Before Vacc 1 >=1:128 | 4.5 (2.3 to 7.7) | 4.0 (2.5 to 6.0) | 6.8 (4.1 to 10.6) | 9.2 (6.8 to 12.0) |
| MenC Before Vacc 2 >=1:4 | 95.0 (91.4 to 97.4) | 85.9 (82.3 to 88.9) | 99.6 (97.7 to 100.0) | 99.4 (98.2 to 99.9) |
| MenC Before Vacc 2 >=1:8 | 92.9 (88.9 to 95.8) | 76.5 (72.4 to 80.3) | 98.4 (95.8 to 99.5) | 98.3 (96.7 to 99.3) |
| MenC Before Vacc 2 >=1:16 | 84.9 (79.8 to 89.2) | 68.3 (63.8 to 72.5) | 98.4 (95.8 to 99.5) | 97.3 (95.4 to 98.5) |
| MenC Before Vacc 2 >=1:32 | 68.2 (61.9 to 74.1) | 52.4 (47.7 to 57.0) | 95.9 (92.6 to 98.0) | 91.6 (88.7 to 93.9) |
| MenC Before Vacc 2 >=1:64 | 53.1 (46.6 to 59.6) | 39.3 (34.9 to 44.0) | 92.6 (88.5 to 95.6) | 81.2 (77.4 to 84.6) |
| MenC Before Vacc 2 >=1:128 | 36.8 (30.7 to 43.3) | 27.8 (23.8 to 32.2) | 78.2 (72.5 to 83.2) | 66.2 (61.8 to 70.5) |
| MenW Before Vacc 1 >=1:4 | 47.8 (41.6 to 53.9) | 50.5 (46.1 to 54.8) | 83.0 (77.4 to 87.8) | 76.3 (71.9 to 80.3) |
| MenW Before Vacc 1 >=1:8 | 32.1 (26.5 to 38.0) | 34.5 (30.5 to 38.8) | 61.9 (55.1 to 68.4) | 60.8 (55.9 to 65.5) |
| MenW Before Vacc 1 >=1:16 | 23.9 (18.9 to 29.4) | 22.8 (19.3 to 26.6) | 37.6 (31.2 to 44.4) | 39.7 (35.0 to 44.6) |
| MenW Before Vacc 1 >=1:32 | 10.8 (7.4 to 15.2) | 13.7 (10.8 to 16.9) | 20.2 (15.1 to 26.1) | 21.8 (17.9 to 26.0) |
| MenW Before Vacc 1 >=1:64 | 7.5 (4.6 to 11.3) | 6.3 (4.3 to 8.7) | 9.2 (5.7 to 13.8) | 11.2 (8.4 to 14.7) |
| MenW Before Vacc 1 >=1:128 | 4.5 (2.3 to 7.7) | 1.5 (0.7 to 3.0) | 5.5 (2.9 to 9.4) | 6.2 (4.1 to 9.0) |
| MenW Before Vacc 2 >=1:4 | 99.2 (97.0 to 99.9) | 96.6 (94.5 to 98.0) | 100.0 (98.2 to 100.0) | 99.0 (97.4 to 99.7) |
| MenW Before Vacc 2 >=1:8 | 99.2 (97.0 to 99.9) | 91.0 (88.0 to 93.4) | 100.0 (98.2 to 100.0) | 99.0 (97.4 to 99.7) |
| MenW Before Vacc 2 >=1:16 | 95.5 (92.0 to 97.7) | 82.7 (78.9 to 86.0) | 99.5 (97.2 to 100.0) | 97.7 (95.6 to 98.9) |
| MenW Before Vacc 2 >=1:32 | 78.5 (72.8 to 83.5) | 64.2 (59.7 to 68.6) | 98.5 (95.7 to 99.7) | 95.8 (93.3 to 97.6) |
| MenW Before Vacc 2 >=1:64 | 56.6 (50.1 to 62.9) | 41.1 (36.6 to 45.7) | 95.5 (91.6 to 97.9) | 89.1 (85.5 to 92.0) |
| MenW Before Vacc 2 >=1:128 | 34.3 (28.3 to 40.6) | 24.2 (20.4 to 28.3) | 84.4 (78.6 to 89.2) | 79.0 (74.5 to 82.9) |
| MenY Before Vacc 1 >=1:4 | 67.2 (61.2 to 72.8) | 70.3 (66.2 to 74.1) | 87.7 (82.6 to 91.7) | 89.5 (86.2 to 92.3) |
| MenY Before Vacc 1 >=1:8 | 54.0 (47.8 to 60.1) | 58.1 (53.8 to 62.4) | 79.9 (74.0 to 85.0) | 77.9 (73.6 to 81.8) |
| MenY Before Vacc 1 >=1:16 | 44.2 (38.1 to 50.4) | 46.6 (42.3 to 50.9) | 67.1 (60.5 to 73.3) | 65.8 (61.0 to 70.3) |
| MenY Before Vacc 1 >=1:32 | 21.1 (16.4 to 26.5) | 26.7 (23.0 to 30.7) | 38.4 (31.9 to 45.1) | 40.9 (36.1 to 45.7) |
| MenY Before Vacc 1 >=1:64 | 10.9 (7.5 to 15.3) | 11.2 (8.6 to 14.2) | 21.9 (16.6 to 28.0) | 20.2 (16.5 to 24.3) |
| MenY Before Vacc 1 >=1:128 | 4.9 (2.6 to 8.2) | 6.3 (4.3 to 8.7) | 10.0 (6.4 to 14.8) | 10.5 (7.7 to 13.8) |
| MenY Before Vacc 2 >=1:4 | 100.0 (98.5 to 100.0) | 98.9 (97.5 to 99.6) | 100.0 (98.2 to 100.0) | 99.5 (98.1 to 99.9) |
| MenY Before Vacc 2 >=1:8 | 100.0 (98.5 to 100.0) | 97.2 (95.2 to 98.5) | 100.0 (98.2 to 100.0) | 99.5 (98.1 to 99.9) |
| MenY Before Vacc 2 >=1:16 | 98.3 (95.8 to 99.5) | 92.9 (90.1 to 95.0) | 100.0 (98.2 to 100.0) | 99.2 (97.7 to 99.8) |
| MenY Before Vacc 2 >=1:32 | 87.0 (82.1 to 91.0) | 77.1 (73.0 to 80.9) | 99.0 (96.4 to 99.9) | 95.8 (93.3 to 97.6) |
| MenY Before Vacc 2 >=1:64 | 69.9 (63.6 to 75.6) | 56.2 (51.5 to 60.7) | 94.9 (90.9 to 97.6) | 88.5 (84.8 to 91.5) |
| MenY Before Vacc 2 >=1:128 | 41.0 (34.7 to 47.5) | 31.1 (26.9 to 35.5) | 86.4 (80.8 to 90.8) | 80.6 (76.3 to 84.5) |
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. Confidence intervals were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the concentrations, or the mean of the ratio.
| Titers | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| MenA Before Vacc 1 | 5.7 (5.1 to 6.3) | 6.3 (5.7 to 6.8) | 11.0 (9.3 to 13.0) | 10.7 (9.6 to 12.0) |
| MenA Before Vacc 2 | 42.7 (36.1 to 50.4) | 47.2 (40.8 to 54.5) | 158.7 (132.6 to 189.8) | 214.6 (187.7 to 245.3) |
| MenC Before Vacc 1 | 7.5 (6.6 to 8.5) | 7.5 (6.8 to 8.2) | 11.9 (10.2 to 13.8) | 13.4 (11.9 to 15.1) |
| MenC Before Vacc 2 | 61.5 (49.5 to 76.3) | 32.7 (27.8 to 38.5) | 253.1 (213.0 to 300.8) | 186.7 (161.9 to 215.2) |
| MenW Before Vacc 1 | 7.0 (6.2 to 7.9) | 7.0 (6.4 to 7.5) | 10.5 (9.1 to 12.2) | 11.0 (9.8 to 12.3) |
| MenW Before Vacc 2 | 62.6 (53.5 to 73.1) | 39.1 (34.4 to 44.5) | 376.8 (311.4 to 456.0) | 255.5 (221.4 to 295.0) |
| MenY Before Vacc 1 | 10.5 (9.1 to 12.1) | 11.5 (10.4 to 12.7) | 19.2 (16.3 to 22.5) | 19.0 (16.8 to 21.4) |
| MenY Before Vacc 2 | 83.6 (71.4 to 97.8) | 58.6 (52.0 to 66.0) | 395.2 (327.8 to 476.3) | 264.0 (228.5 to 305.0) |
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
| Percentage of participants | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) Before Vacc 1 | 25.3 (21.2 to 29.7) | 25.1 (22.2 to 28.2) |
| PMB80 (A22) Before Vacc 2 | 41.6 (36.9 to 46.5) | 41.9 (38.6 to 45.3) |
| PMB2001 (A56) Before Vacc 1 | 13.8 (10.6 to 17.4) | 12.8 (10.6 to 15.3) |
| PMB2001 (A56) Before Vacc 2 | 52.2 (47.2 to 57.1) | 45.7 (42.3 to 49.2) |
| PMB2948 (B24) Before Vacc 1 | 10.4 (7.7 to 13.6) | 11.9 (9.8 to 14.3) |
| PMB2948 (B24) Before Vacc 2 | 26.5 (22.4 to 31.0) | 24.2 (21.3 to 27.2) |
| PMB2707 (B44) Before Vacc 1 | 3.7 (2.1 to 5.9) | 4.5 (3.2 to 6.1) |
| PMB2707 (B44) Before Vacc 2 | 18.8 (15.1 to 22.8) | 16.5 (14.0 to 19.2) |
Percentage of participants who achieved an hSBA titer \>=1:4, \>=1:8, \>=1:16, \>=1:32, \>=1:64, and \>=1:128 for each of the 4 primary MenB test strains was reported in this outcome measure.
| Percentage of participants | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) Before Vacc 1 >=1:4 | 34.7 (30.1 to 39.4) | 36.6 (33.3 to 40.0) |
| PMB80 (A22) Before Vacc 1 >=1:8 | 31.9 (27.5 to 36.5) | 31.8 (28.7 to 35.1) |
| PMB80 (A22) Before Vacc 1 >=1:16 | 25.3 (21.2 to 29.7) | 25.1 (22.2 to 28.2) |
| PMB80 (A22) Before Vacc 1 >=1:32 | 11.0 (8.2 to 14.4) | 11.4 (9.4 to 13.8) |
| PMB80 (A22) Before Vacc 1 >=1:64 | 4.7 (2.9 to 7.1) | 4.4 (3.1 to 6.0) |
| PMB80 (A22) Before Vacc 1 >=1:128 | 1.4 (0.5 to 3.0) | 0.8 (0.3 to 1.7) |
| PMB80 (A22) Before Vacc 2 >=1:4 | 48.2 (43.4 to 53.1) | 49.8 (46.3 to 53.2) |
| PMB80 (A22) Before Vacc 2 >=1:8 | 44.5 (39.7 to 49.3) | 46.6 (43.1 to 50.0) |
| PMB80 (A22) Before Vacc 2 >=1:16 | 41.6 (36.9 to 46.5) | 41.9 (38.6 to 45.3) |
| PMB80 (A22) Before Vacc 2 >=1:32 | 23.5 (19.6 to 27.9) | 23.5 (20.7 to 26.5) |
| PMB80 (A22) Before Vacc 2 >=1:64 | 9.9 (7.2 to 13.1) | 9.0 (7.2 to 11.2) |
| PMB80 (A22) Before Vacc 2 >=1:128 | 2.6 (1.3 to 4.6) | 3.2 (2.1 to 4.6) |
| PMB2001 (A56) Before Vacc 1 >=1:4 | 19.5 (15.8 to 23.6) | 17.5 (15.0 to 20.3) |
| PMB2001 (A56) Before Vacc 1 >=1:8 | 13.8 (10.6 to 17.4) | 12.8 (10.6 to 15.3) |
| PMB2001 (A56) Before Vacc 1 >=1:16 | 10.7 (7.9 to 14.0) | 11.0 (9.0 to 13.4) |
| PMB2001 (A56) Before Vacc 1 >=1:32 | 6.7 (4.5 to 9.5) | 7.6 (5.9 to 9.6) |
| PMB2001 (A56) Before Vacc 1 >=1:64 | 3.8 (2.2 to 6.1) | 4.3 (3.0 to 5.9) |
| PMB2001 (A56) Before Vacc 1 >=1:128 | 2.9 (1.5 to 4.9) | 2.4 (1.5 to 3.7) |
| PMB2001 (A56) Before Vacc 2 >=1:4 | 56.6 (51.6 to 61.4) | 50.6 (47.1 to 54.1) |
| PMB2001 (A56) Before Vacc 2 >=1:8 | 52.2 (47.2 to 57.1) | 45.7 (42.3 to 49.2) |
| PMB2001 (A56) Before Vacc 2 >=1:16 | 47.1 (42.2 to 52.0) | 41.2 (37.8 to 44.7) |
| PMB2001 (A56) Before Vacc 2 >=1:32 | 35.2 (30.6 to 40.0) | 30.9 (27.8 to 34.3) |
| PMB2001 (A56) Before Vacc 2 >=1:64 | 21.4 (17.5 to 25.6) | 19.0 (16.3 to 21.9) |
| PMB2001 (A56) Before Vacc 2 >=1:128 | 10.0 (7.2 to 13.3) | 9.5 (7.6 to 11.7) |
| PMB2948 (B24) Before Vacc 1 >=1:4 | 14.1 (10.9 to 17.7) | 14.6 (12.3 to 17.2) |
| PMB2948 (B24) Before Vacc 1 >=1:8 | 10.4 (7.7 to 13.6) | 11.9 (9.8 to 14.3) |
| PMB2948 (B24) Before Vacc 1 >=1:16 | 6.2 (4.1 to 8.9) | 8.2 (6.4 to 10.2) |
| PMB2948 (B24) Before Vacc 1 >=1:32 | 3.7 (2.1 to 5.9) | 4.2 (3.0 to 5.8) |
| PMB2948 (B24) Before Vacc 1 >=1:64 | 0.9 (0.3 to 2.3) | 2.3 (1.4 to 3.6) |
| PMB2948 (B24) Before Vacc 1 >=1:128 | 0.2 (0.0 to 1.3) | 1.1 (0.5 to 2.0) |
| PMB2948 (B24) Before Vacc 2 >=1:4 | 30.5 (26.1 to 35.1) | 28.0 (25.0 to 31.2) |
| PMB2948 (B24) Before Vacc 2 >=1:8 | 26.5 (22.4 to 31.0) | 24.2 (21.3 to 27.2) |
| PMB2948 (B24) Before Vacc 2 >=1:16 | 21.4 (17.6 to 25.6) | 20.2 (17.5 to 23.0) |
| PMB2948 (B24) Before Vacc 2 >=1:32 | 11.2 (8.3 to 14.5) | 11.0 (9.0 to 13.3) |
| PMB2948 (B24) Before Vacc 2 >=1:64 | 5.1 (3.2 to 7.6) | 5.7 (4.2 to 7.5) |
| PMB2948 (B24) Before Vacc 2 >=1:128 | 2.3 (1.1 to 4.2) | 2.3 (1.4 to 3.5) |
| PMB2707 (B44) Before Vacc 1 >=1:4 | 7.1 (4.9 to 10.0) | 7.2 (5.6 to 9.1) |
| PMB2707 (B44) Before Vacc 1 >=1:8 | 3.7 (2.1 to 5.9) | 4.5 (3.2 to 6.1) |
| PMB2707 (B44) Before Vacc 1 >=1:16 | 2.1 (1.0 to 3.9) | 3.3 (2.2 to 4.7) |
| PMB2707 (B44) Before Vacc 1 >=1:32 | 0.9 (0.3 to 2.3) | 2.1 (1.2 to 3.3) |
| PMB2707 (B44) Before Vacc 1 >=1:64 | 0.7 (0.1 to 2.0) | 1.2 (0.6 to 2.1) |
| PMB2707 (B44) Before Vacc 1 >=1:128 | 0.5 (0.1 to 1.7) | 0.3 (0.1 to 1.0) |
| PMB2707 (B44) Before Vacc 2 >=1:4 | 29.2 (24.9 to 33.8) | 25.7 (22.8 to 28.8) |
| PMB2707 (B44) Before Vacc 2 >=1:8 | 18.8 (15.1 to 22.8) | 16.5 (14.0 to 19.2) |
| PMB2707 (B44) Before Vacc 2 >=1:16 | 13.5 (10.4 to 17.2) | 11.7 (9.6 to 14.1) |
| PMB2707 (B44) Before Vacc 2 >=1:32 | 7.6 (5.3 to 10.6) | 5.8 (4.3 to 7.6) |
| PMB2707 (B44) Before Vacc 2 >=1:64 | 3.3 (1.8 to 5.5) | 2.8 (1.8 to 4.2) |
| PMB2707 (B44) Before Vacc 2 >=1:128 | 0.7 (0.1 to 2.1) | 1.4 (0.7 to 2.5) |
GMTs were calculated using all participants with valid and determinate hSBA titers at the given time point. LLOQ =1:16 for A22; 1:8 for A56, B24, and B44. Titers below the LLOQ were set to 0.5\*LLOQ for analysis. CIs were back transformations of confidence levels based on the Student t distribution for the mean logarithm of the hSBA titers.
| Titers | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22), Before vacc 1 | 10.8 (10.2 to 11.5) | 10.7 (10.3 to 11.1) |
| PMB80 (A22), Before vacc 2 | 13.7 (12.8 to 14.8) | 13.8 (13.1 to 14.5) |
| PMB2001 (A56), Before vacc 1 | 5.2 (4.9 to 5.7) | 5.3 (5.0 to 5.6) |
| PMB2001 (A56), Before vacc 2 | 13.0 (11.4 to 14.8) | 11.4 (10.4 to 12.5) |
| PMB2948 (B24), Before vacc 1 | 4.6 (4.4 to 4.9) | 4.9 (4.7 to 5.1) |
| PMB2948 (B24), Before vacc 2 | 6.3 (5.8 to 6.9) | 6.2 (5.9 to 6.6) |
| PMB2707 (B44), Before vacc 1 | 4.2 (4.1 to 4.4) | 4.3 (4.2 to 4.5) |
| PMB2707 (B44), Before vacc 2 | 5.4 (5.1 to 5.8) | 5.3 (5.0 to 5.5) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY Test Strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|
| MenA 12 Months after Vacc 2 | 91.1 (84.2 to 95.6) | 71.2 (57.9 to 82.2) | 97.9 (88.9 to 99.9) | 100.0 (84.6 to 100.0) |
| MenA 24 Months after Vacc 2 | 88.1 (80.2 to 93.7) | 70.0 (56.8 to 81.2) | 100.0 (94.1 to 100.0) | 100.0 (90.5 to 100.0) |
| MenA 36 Months after Vacc 2 | 88.4 (80.2 to 94.1) | 72.2 (58.4 to 83.5) | 100.0 (93.7 to 100.0) | 97.0 (84.2 to 99.9) |
| MenA 48 Months after Vacc 2 | 81.7 (70.7 to 89.9) | 63.4 (46.9 to 77.9) | 100.0 (91.2 to 100.0) | 100.0 (85.2 to 100.0) |
| MenC 12 Months after Vacc 2 | 76.8 (67.9 to 84.2) | 51.6 (38.6 to 64.5) | 96.3 (87.3 to 99.5) | 91.3 (72.0 to 98.9) |
| MenC 24 Months after Vacc 2 | 75.2 (65.7 to 83.3) | 47.5 (34.6 to 60.7) | 96.9 (91.2 to 99.4) | 94.4 (86.2 to 98.4) |
| MenC 36 Months after Vacc 2 | 67.4 (57.0 to 76.6) | 44.4 (30.9 to 58.6) | 96.9 (91.1 to 99.4) | 95.5 (87.5 to 99.1) |
| MenC 48 Months after Vacc 2 | 62.0 (49.7 to 73.2) | 38.1 (23.6 to 54.4) | 98.7 (92.9 to 100.0) | 89.7 (78.8 to 96.1) |
| MenW 12 Months after Vacc 2 | 99.1 (95.1 to 100.0) | 83.9 (72.3 to 92.0) | 100.0 (92.6 to 100.0) | 95.5 (77.2 to 99.9) |
| MenW 24 Months after Vacc 2 | 99.0 (94.7 to 100.0) | 78.7 (66.3 to 88.1) | 100.0 (94.1 to 100.0) | 94.6 (81.8 to 99.3) |
| MenW 36 Months after Vacc 2 | 94.8 (88.4 to 98.3) | 77.8 (64.4 to 88.0) | 100.0 (93.7 to 100.0) | 97.0 (84.2 to 99.9) |
| MenW 48 Months after Vacc 2 | 91.4 (82.3 to 96.8) | 70.7 (54.5 to 83.9) | 100.0 (91.2 to 100.0) | 91.3 (72.0 to 98.9) |
| MenY 12 Months after Vacc 2 | 100.0 (96.8 to 100.0) | 98.4 (91.3 to 100.0) | 100.0 (92.6 to 100.0) | 100.0 (84.6 to 100.0) |
| MenY 24 Months after Vacc 2 | 100.0 (96.4 to 100.0) | 93.4 (84.1 to 98.2) | 100.0 (94.1 to 100.0) | 100.0 (90.5 to 100.0) |
| MenY 36 Months after Vacc 2 | 100.0 (96.3 to 100.0) | 90.7 (79.7 to 96.9) | 100.0 (93.7 to 100.0) | 100.0 (84.2 to 100.0) |
| MenY 48 Months after Vacc 2 | 100.0 (94.9 to 100.0) | 95.2 (83.8 to 99.4) | 100.0 (91.2 to 100.0) | 100.0 (84.6 to 100.0) |
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
| Percentage of participants | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) 12 months after Vacc 2 | 32.7 (25.6 to 40.5) | 26.5 (17.4 to 37.3) |
| PMB80 (A22) 24 months after Vacc 2 | 36.7 (30.0 to 43.9) | 28.9 (21.2 to 37.6) |
| PMB80 (A22) 36 months after Vacc 2 | 29.2 (22.8 to 36.3) | 25.9 (18.2 to 34.8) |
| PMB80 (A22) 48 months after Vacc 2 | 28.1 (20.8 to 36.3) | 31.9 (22.7 to 42.3) |
| PMB2001 (A56) 12 months after Vacc 2 | 33.3 (26.1 to 41.2) | 32.1 (22.4 to 43.2) |
| PMB2001 (A56) 24 months after Vacc 2 | 34.7 (28.1 to 41.8) | 33.6 (25.6 to 42.4) |
| PMB2001 (A56) 36 months after Vacc 2 | 29.0 (22.6 to 36.1) | 33.9 (25.4 to 43.2) |
| PMB2001 (A56) 48 months after Vacc 2 | 34.5 (26.8 to 42.8) | 29.6 (20.8 to 39.7) |
| PMB2948 (B24) 12 months after Vacc 2 | 30.9 (24.0 to 38.6) | 28.2 (19.0 to 39.0) |
| PMB2948 (B24) 24 months after Vacc 2 | 33.2 (26.6 to 40.2) | 27.5 (20.0 to 36.0) |
| PMB2948 (B24) 36 months after Vacc 2 | 35.4 (28.7 to 42.6) | 28.3 (20.5 to 37.3) |
| PMB2948 (B24) 48 months after Vacc 2 | 36.6 (28.7 to 44.9) | 26.5 (18.1 to 36.4) |
| PMB2707 (B44) 12 months after Vacc 2 | 18.7 (13.1 to 25.4) | 15.3 (8.4 to 24.7) |
| PMB2707 (B44) 24 months after Vacc 2 | 18.0 (12.9 to 24.0) | 18.2 (12.0 to 25.8) |
| PMB2707 (B44) 36 months after Vacc 2 | 20.2 (14.8 to 26.6) | 19.8 (13.1 to 28.1) |
| PMB2707 (B44) 48 months after Vacc 2 | 18.2 (12.4 to 25.4) | 16.2 (9.5 to 24.9) |
Percentage of participants who achieved an hSBA-MenA, hSBA-MenC, hSBA-MenW, and hSBA-MenY titer \>=LLOQ for ACWY test strains (LLOQ = 1:8 for all MenA, MenC, MenW, and MenY strains) was reported in this outcome measure. Analysis was planned for Group 1 and 3 separately.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| MenA | 100.0 (94.0 to 100.0) | 100.0 (89.4 to 100.0) |
| MenC | 100.0 (94.0 to 100.0) | 100.0 (94.9 to 100.0) |
| MenW | 100.0 (94.0 to 100.0) | 100.0 (89.4 to 100.0) |
| MenY | 100.0 (94.0 to 100.0) | 100.0 (89.4 to 100.0) |
Percentage of participants who achieved an hSBA titer \>=LLOQ for all 4 primary MenB test strains (LLOQ was 1:16 for A22 and 1:8 for A56, B24, and B44) was reported in this outcome measure.
| Percentage of participants | Group 1+3 Combined (MenABCWY + Saline) | Groups 2+4 Combined (Bivalent rLP2086 + MenACWY-CRM) |
|---|---|---|
| PMB80 (A22) | 95.1 (89.6 to 98.2) | 93.8 (86.2 to 98.0) |
| PMB2001 (A56) | 100.0 (97.1 to 100.0) | 98.8 (93.7 to 100.0) |
| PMB2948 (B24) | 95.1 (89.7 to 98.2) | 95.2 (88.3 to 98.7) |
| PMB2707 (B44) | 99.2 (95.7 to 100.0) | 98.8 (93.7 to 100.0) |
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Redness: Any | 19.7 (15.1 to 25.0) | 14.9 (10.8 to 19.7) |
| Redness: Mild | 7.4 (4.6 to 11.2) | 5.6 (3.2 to 9.0) |
| Redness: Moderate | 10.0 (6.7 to 14.3) | 7.4 (4.6 to 11.2) |
| Redness: Severe | 2.2 (0.8 to 4.8) | 1.9 (0.6 to 4.3) |
| Swelling: Any | 20.8 (16.1 to 26.2) | 17.5 (13.1 to 22.5) |
| Swelling: Mild | 9.3 (6.1 to 13.4) | 8.6 (5.5 to 12.6) |
| Swelling: Moderate | 10.4 (7.0 to 14.7) | 8.6 (5.5 to 12.6) |
| Swelling: Severe | 1.1 (0.2 to 3.2) | 0.4 (0.0 to 2.1) |
| Pain at injection site: Any | 89.2 (84.9 to 92.7) | 90.3 (86.2 to 93.6) |
| Pain at injection site: Mild | 37.2 (31.4 to 43.3) | 45.4 (39.3 to 51.5) |
| Pain at injection site: Moderate | 45.7 (39.7 to 51.9) | 40.1 (34.2 to 46.3) |
| Pain at injection site: Severe | 6.3 (3.7 to 9.9) | 4.8 (2.6 to 8.1) |
Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in e-diary. Redness and swelling were measured and recorded in caliper units. Each caliper unit represented 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Redness: Any | 23.0 (17.8 to 29.0) | 19.3 (14.4 to 25.0) |
| Redness: Mild | 7.0 (4.0 to 11.1) | 6.9 (4.0 to 10.9) |
| Redness: Moderate | 11.7 (7.9 to 16.6) | 9.0 (5.7 to 13.4) |
| Redness: Severe | 4.3 (2.1 to 7.9) | 3.4 (1.5 to 6.7) |
| Swelling: Any | 19.1 (14.3 to 24.8) | 18.0 (13.3 to 23.6) |
| Swelling: Mild | 8.7 (5.4 to 13.1) | 5.6 (3.0 to 9.4) |
| Swelling: Moderate | 10.0 (6.4 to 14.6) | 11.2 (7.4 to 15.9) |
| Swelling: Severe | 0.4 (0.0 to 2.4) | 1.3 (0.3 to 3.7) |
| Pain at injection site: Any | 85.2 (80.0 to 89.5) | 83.7 (78.3 to 88.2) |
| Pain at injection site: Mild | 34.3 (28.2 to 40.9) | 37.8 (31.5 to 44.3) |
| Pain at injection site: Moderate | 47.0 (40.4 to 53.6) | 38.2 (31.9 to 44.8) |
| Pain at injection site: Severe | 3.9 (1.8 to 7.3) | 7.7 (4.6 to 11.9) |
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Fever: >= 38.0 degree C | 7.4 (4.6 to 11.2) | 5.2 (2.9 to 8.6) |
| Fever: 38.0 to 38.4 degree C | 4.1 (2.1 to 7.2) | 4.1 (2.1 to 7.2) |
| Fever: 38.4 to 38.9 degree C | 2.2 (0.8 to 4.8) | 0.7 (0.1 to 2.7) |
| Fever: 38.9 to 40.0 degree C | 1.1 (0.2 to 3.2) | 0.4 (0.0 to 2.1) |
| Fever: > 40.0 degree C | 0.0 (0.0 to 1.4) | 0.0 (0.0 to 1.4) |
| Fatigue: Any | 56.5 (50.4 to 62.5) | 49.1 (42.9 to 55.2) |
| Fatigue: Mild | 26.8 (21.6 to 32.5) | 27.9 (22.6 to 33.6) |
| Fatigue: Moderate | 25.3 (20.2 to 30.9) | 17.5 (13.1 to 22.5) |
| Fatigue: Severe | 4.5 (2.3 to 7.7) | 3.7 (1.8 to 6.7) |
| Headache: Any | 48.3 (42.2 to 54.5) | 45.0 (38.9 to 51.1) |
| Headache: Mild | 27.1 (21.9 to 32.9) | 29.4 (24.0 to 35.2) |
| Headache: Moderate | 19.3 (14.8 to 24.6) | 14.1 (10.2 to 18.9) |
| Headache: Severe | 1.9 (0.6 to 4.3) | 1.5 (0.4 to 3.8) |
| Chills: Any | 20.1 (15.5 to 25.4) | 14.9 (10.8 to 19.7) |
| Chills: Mild | 14.5 (10.5 to 19.3) | 9.3 (6.1 to 13.4) |
| Chills: Moderate | 4.5 (2.3 to 7.7) | 4.8 (2.6 to 8.1) |
| Chills: Severe | 1.1 (0.2 to 3.2) | 0.7 (0.1 to 2.7) |
| Vomiting: Any | 2.6 (1.1 to 5.3) | 1.9 (0.6 to 4.3) |
| Vomiting: Mild | 2.2 (0.8 to 4.8) | 1.9 (0.6 to 4.3) |
| Vomiting: Moderate | 0.4 (0.0 to 2.1) | 0.0 (0.0 to 1.4) |
| Vomiting: severe | 0.0 (0.0 to 1.4) | 0.0 (0.0 to 1.4) |
| Diarrhea: Any | 12.3 (8.6 to 16.8) | 15.2 (11.2 to 20.1) |
| Diarrhea: Mild | 10.0 (6.7 to 14.3) | 10.8 (7.3 to 15.1) |
| Diarrhea: Moderate | 2.2 (0.8 to 4.8) | 4.5 (2.3 to 7.7) |
| Diarrhea: Severe | 0.0 (0.0 to 1.4) | 0.0 (0.0 to 1.4) |
| Muscle pain: Any | 29.0 (23.6 to 34.8) | 22.7 (17.8 to 28.2) |
| Muscle pain: Mild | 17.1 (12.8 to 22.1) | 14.5 (10.5 to 19.3) |
| Muscle pain: Moderate | 10.4 (7.0 to 14.7) | 7.1 (4.3 to 10.8) |
| Muscle pain: Severe | 1.5 (0.4 to 3.8) | 1.1 (0.2 to 3.2) |
| Joint pain: Any | 20.8 (16.1 to 26.2) | 18.2 (13.8 to 23.4) |
| Joint pain: Mild | 13.0 (9.2 to 17.6) | 10.8 (7.3 to 15.1) |
| Joint pain: Moderate | 7.8 (4.9 to 11.7) | 6.7 (4.0 to 10.4) |
| Joint pain: Severe | 0.0 (0.0 to 1.4) | 0.7 (0.1 to 2.7) |
Systemic events fever, vomiting, diarrhea, headache, fatigue, chills, muscle pain and joint pain were recorded in an e-diary. Fever was defined as \>=38.0 degree C and categorized to 38.0 to 38.4 degree C, 38.5 to 38.9 degree C, 39.0 to 40.0 degree C and \>40.0 degree C. Headache, fatigue, chills, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting was graded as mild (1-2 times in 24 hours), moderate (\>2 times in 24 hours) and severe (required IV hydration). Diarrhea was graded as mild (2-3 loose stools in 24 hours), moderate (4-5 loose stools in 24 hours) and severe (\>=6 in 24 hours).
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Fever: >= 38.0 degree C | 3.5 (1.5 to 6.7) | 1.7 (0.5 to 4.3) |
| Fever: 38.0 to 38.4°C | 2.2 (0.7 to 5.0) | 0.9 (0.1 to 3.1) |
| Fever: 38.5 to 38.9°C | 1.3 (0.3 to 3.8) | 0.9 (0.1 to 3.1) |
| Fever: 39.0 to 40.0°C | 0.0 (0.0 to 1.6) | 0.0 (0.0 to 1.6) |
| Fever: > 40.0°C | 0.0 (0.0 to 1.6) | 0.0 (0.0 to 1.6) |
| Fatigue: Any | 49.6 (42.9 to 56.2) | 47.6 (41.1 to 54.3) |
| Fatigue: Mild | 20.9 (15.8 to 26.7) | 26.2 (20.7 to 32.3) |
| Fatigue: Moderate | 26.1 (20.5 to 32.3) | 18.9 (14.1 to 24.5) |
| Fatigue: Severe | 2.6 (1.0 to 5.6) | 2.6 (1.0 to 5.5) |
| Headache: Any | 41.7 (35.3 to 48.4) | 43.8 (37.3 to 50.4) |
| Headache: Mild | 22.6 (17.4 to 28.6) | 26.6 (21.1 to 32.8) |
| Headache: Moderate | 17.8 (13.1 to 23.4) | 13.3 (9.2 to 18.4) |
| Headache: Severe | 1.3 (0.3 to 3.8) | 3.9 (1.8 to 7.2) |
| Chills: Any | 20.9 (15.8 to 26.7) | 19.3 (14.4 to 25.0) |
| Chills: Mild | 16.1 (11.6 to 21.5) | 11.6 (7.8 to 16.4) |
| Chills: Moderate | 3.9 (1.8 to 7.3) | 5.2 (2.7 to 8.8) |
| Chills: Severe | 0.9 (0.1 to 3.1) | 2.6 (1.0 to 5.5) |
| Vomiting: Any | 1.7 (0.5 to 4.4) | 3.9 (1.8 to 7.2) |
| Vomiting: Mild | 1.7 (0.5 to 4.4) | 3.4 (1.5 to 6.7) |
| Vomiting: Moderate | 0.0 (0.0 to 1.6) | 0.4 (0.0 to 2.4) |
| Vomiting: Severe | 0.0 (0.0 to 1.6) | 0.0 (0.0 to 1.6) |
| Diarrhea: Any | 13.5 (9.3 to 18.6) | 8.2 (5.0 to 12.4) |
| Diarrhea: Mild | 9.6 (6.1 to 14.1) | 5.2 (2.7 to 8.8) |
| Diarrhea: Moderate | 3.9 (1.8 to 7.3) | 2.6 (1.0 to 5.5) |
| Diarrhea: Severe | 0.0 (0.0 to 1.6) | 0.4 (0.0 to 2.4) |
| Muscle pain: Any | 24.8 (19.3 to 30.9) | 19.3 (14.4 to 25.0) |
| Muscle pain: Mild | 13.0 (9.0 to 18.1) | 8.6 (5.3 to 12.9) |
| Muscle pain: Moderate | 10.9 (7.2 to 15.6) | 9.9 (6.4 to 14.4) |
| Muscle pain: Severe | 0.9 (0.1 to 3.1) | 0.9 (0.1 to 3.1) |
| Joint pain: Any | 18.7 (13.9 to 24.3) | 18.0 (13.3 to 23.6) |
| Joint pain: Mild | 9.1 (5.7 to 13.6) | 10.7 (7.1 to 15.4) |
| Joint pain: Moderate | 9.1 (5.7 to 13.6) | 6.4 (3.6 to 10.4) |
| Joint pain: Severe | 0.4 (0.0 to 2.4) | 0.9 (0.1 to 3.1) |
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 1: Group 1 and Group 3 | 20.8 (16.1 to 26.2) | 13.8 (9.9 to 18.5) |
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With Antipyretic Medication Use 30 Days After Vaccination 2: Group 1 and Group 3 | 17.8 (13.1 to 23.4) | 13.3 (9.2 to 18.4) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 1: Group 1 and Group 3 | 0.0 (0.0 to 1.3) | 0.7 (0.1 to 2.6) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Vaccination 2: Group 1 and Group 3 | 0.4 (0.0 to 2.3) | 0.0 (0.0 to 1.5) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE Within 30 Days After Any Vaccination: Group 1 and Group 3 | 0.4 (0.0 to 2.0) | 0.7 (0.1 to 2.6) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE During the Vaccination Phase: Group 1 and Group 3 | 0.4 (0.0 to 2.0) | 1.8 (0.6 to 4.3) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE During the Stage 1 Follow-up Phase: Group 1 and Group 3 | 0.8 (0.1 to 3.0) | 0.4 (0.0 to 2.3) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event. There was one participant who did not meet criteria for Stage 1 follow-up safety population. The subject's SAE happened in the follow-up phase but was not included in the follow-up safety population for Stage 1 (but in the safety population for Stage 1). Therefore, the SAE was not included in the follow-up table but in the broadly defined throughout Stage 1 table.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 SAE Throughout the Stage 1: Group 1 and Group 3 | 1.5 (0.4 to 3.7) | 2.2 (0.8 to 4.8) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 1: Group 1 and Group 3 | 4.8 (2.6 to 8.0) | 5.9 (3.4 to 9.4) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Vaccination 2: Group 1 and Group 3 | 5.8 (3.2 to 9.5) | 9.0 (5.7 to 13.3) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Within 30 Days After Any Vaccination: Group 1 and Group 3 | 9.6 (6.3 to 13.7) | 13.3 (9.5 to 17.9) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Vaccination Phase: Group 1 and Group 3 | 23.9 (19.0 to 29.4) | 28.4 (23.1 to 34.2) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE During the Stage 1 Follow-up Phase: Group 1 and Group 3 | 13.8 (9.7 to 18.8) | 18.8 (14.1 to 24.4) |
Medically attended AE was defined as a nonserious AE that resulted in an evaluation at a medical facility.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Medically Attended AE Throughout the Stage 1: Group 1 and Group 3 | 30.9 (25.4 to 36.7) | 35.1 (29.4 to 41.1) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 1: Group 1 and Group 3 | 0.0 (0.0 to 1.3) | 0.0 (0.0 to 1.4) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Vaccination 2: Group 1 and Group 3 | 0.0 (0.0 to 1.5) | 0.0 (0.0 to 1.5) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 NDCMC Within 30 Days After Any Vaccination: Group 1 and Group 3 | 0.0 (0.0 to 1.3) | 0.0 (0.0 to 1.4) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Vaccination Phase: Group 1 and Group 3 | 0.7 (0.1 to 2.6) | 0.0 (0.0 to 1.4) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 NDCMC During the Stage 1 Follow-up Phase: Group 1 and Group 3 | 0.4 (0.0 to 2.3) | 0.0 (0.0 to 1.5) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 NDCMC Throughout the Stage 1: Group 1 and Group 3 | 1.1 (0.2 to 3.2) | 0.0 (0.0 to 1.4) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 1: Group 1 and Group 3 | 15.1 (11.0 to 19.9) | 11.1 (7.6 to 15.4) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination 2: Group 1 and Group 3 | 16.1 (11.7 to 21.4) | 12.3 (8.5 to 17.1) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 AE Within 30 Days After Vaccination Any Vaccination: Group 1 and Group 3 | 25.7 (20.6 to 31.4) | 19.9 (15.3 to 25.2) |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs did not include local reaction and systemic events collected by systematic approach.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 AE During the Stage 1 Vaccination Phase: Group 1 and Group 3 | 41.5 (35.6 to 47.6) | 36.9 (31.1 to 42.9) |
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 1: Group 1 and Group 3 | 0.0 (0.0 to 1.3) | 0.0 (0.0 to 1.4) |
Immediate AE was defined as AE occurring within the first 30 minutes after investigational product administration.
| Percentage of participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Percentage of Participants With at Least 1 Immediate AE After Vaccination 2: Group 1 and Group 3 | 0.0 (0.0 to 1.5) | 0.0 (0.0 to 1.5) |
| Participants | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) |
|---|---|---|
| Stage1: Number of Participants Who Missed School/Work Due to AE During the Stage 1 Vaccination Phase: Group 1 and Group 3 | 38 | 46 |
Collected over Systematic assessment: Local reactions and systemic events recorded within 7 days of each vaccination; Non-systematic collection: SAEs recorded from Month 0 to 6 months after Vaccination 2 (up to Month 12) and 6 months after Booster Vaccination (Booster Vaccination was at Month 54); Non-SAEs recorded from Month 0 to 1 month after Vaccination 2 ( up to Month 7); within 48 hours of blood draw at Month 18, 30 and 42; and 1 month after Booster Vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Stage 1: Group 1: MenABCWY + Saline (ACWY-Naive) | 1/272 (0.4%) | 5/272 (1.8%) | 267/272 (98.2%) |
| Stage 1: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | 0/534 (0%) | 6/534 (1.1%) | 508/534 (95.1%) |
| Stage 1: Group 3: MenABCWY + Saline (ACWY-Experienced) | 0/271 (0%) | 6/271 (2.2%) | 259/271 (95.6%) |
| Stage 1: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | 0/523 (0%) | 9/523 (1.7%) | 502/523 (96%) |
| Stage 2: Group 1: MenABCWY + Saline (ACWY-Naive) | 0/114 (0%) | 1/114 (0.9%) | 54/114 (47.4%) |
| Stage 2: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | 0/65 (0%) | 1/65 (1.5%) | 37/65 (56.9%) |
| Stage 2: Group 3: MenABCWY + Saline (ACWY-Experienced) | 0/101 (0%) | 3/101 (3%) | 72/101 (71.3%) |
| Stage 2: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | 0/73 (0%) | 2/73 (2.7%) | 57/73 (78.1%) |
| Event | Stage 1: Group 1: MenABCWY + Saline (ACWY-Naive) | Stage 1: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Stage 1: Group 3: MenABCWY + Saline (ACWY-Experienced) | Stage 1: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Stage 2: Group 1: MenABCWY + Saline (ACWY-Naive) | Stage 2: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Stage 2: Group 3: MenABCWY + Saline (ACWY-Experienced) | Stage 2: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/272 | 0/534 | 0/271 | 0/523 | 0/114 | 0/65 | 2/101 | 0/73 |
| Major depressionPsychiatric disorders | 0/272 | 0/534 | 0/271 | 1/523 | 0/114 | 1/65 | 0/101 | 0/73 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 1/272 | 0/534 | 0/271 | 0/523 | 1/114 | 0/65 | 1/101 | 1/73 |
| Psychotic disorderPsychiatric disorders | 0/272 | 0/534 | 0/271 | 0/523 | 0/114 | 0/65 | 0/101 | 1/73 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/272 | 1/534 | 0/271 | 0/523 | 0/114 | 0/65 | 1/101 | 0/73 |
| Suicidal ideationPsychiatric disorders | 0/272 | 0/534 | 2/271 | 0/523 | 0/114 | 0/65 | 0/101 | 0/73 |
| OverdoseInjury, poisoning and procedural complications | 0/272 | 0/534 | 1/271 | 0/523 | 0/114 | 0/65 | 0/101 | 0/73 |
| Tendon injuryInjury, poisoning and procedural complications | 0/272 | 0/534 | 1/271 | 0/523 | 0/114 | 0/65 | 0/101 | 0/73 |
| DyskinesiaNervous system disorders | 0/272 | 0/534 | 1/271 | 0/523 | 0/114 | 0/65 | 0/101 | 0/73 |
| Migraine with auraNervous system disorders | 0/272 | 0/534 | 1/271 | 0/523 | 0/114 | 0/65 | 0/101 | 0/73 |
| Event | Stage 1: Group 1: MenABCWY + Saline (ACWY-Naive) | Stage 1: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Stage 1: Group 3: MenABCWY + Saline (ACWY-Experienced) | Stage 1: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Stage 2: Group 1: MenABCWY + Saline (ACWY-Naive) | Stage 2: Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Stage 2: Group 3: MenABCWY + Saline (ACWY-Experienced) | Stage 2: Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) |
|---|---|---|---|---|---|---|---|---|
| Injection site pain (PAIN AT INJECTION SITE)General disorders | 256/272 | 479/534 | 251/271 | 480/523 | 48/114 | 34/65 | 65/101 | 50/73 |
| FatigueGeneral disorders | 180/272 | 315/534 | 163/271 | 344/523 | 28/114 | 24/65 | 47/101 | 37/73 |
| HeadacheNervous system disorders | 163/272 | 312/534 | 159/271 | 312/523 | 23/114 | 21/65 | 35/101 | 31/73 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 104/272 | 204/534 | 87/271 | 186/523 | 11/114 | 12/65 | 24/101 | 13/73 |
| ChillsGeneral disorders | 82/272 | 152/534 | 67/271 | 141/523 | 6/114 | 7/65 | 14/101 | 8/73 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 79/272 | 153/534 | 78/271 | 148/523 | 12/114 | 10/65 | 16/101 | 9/73 |
| SwellingGeneral disorders | 77/272 | 123/534 | 67/271 | 114/523 | 11/114 | 9/65 | 14/101 | 10/73 |
| Erythema (REDNESS)Skin and subcutaneous tissue disorders | 73/272 | 130/534 | 61/271 | 95/523 | 8/114 | 11/65 | 16/101 | 14/73 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 55/272 | 104/534 | 54/271 | 105/523 | 3/114 | 4/65 | 7/101 | 7/73 |
| Pyrexia (FEVER)General disorders | 29/272 | 56/534 | 17/271 | 37/523 | 3/114 | 1/65 | 0/101 | 1/73 |
The safety population for Stage 1 included participants who had received at least 1 dose of investigational product during Stage 1 and for whom safety data were available.
| Age, Continuous(Years) | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Total |
|---|---|---|---|---|---|
| Stage 1 | 16.0 ± 5.67 | 16.5 ± 5.81 | 17.7 ± 3.57 | 17.8 ± 3.66 | 17.1 ± 4.87 |
| Stage 2 | 19.1 ± 5.36 | 18.5 ± 5.51 | 20.8 ± 3.73 | 21.1 ± 4.11 | 20.4 ± 4.72 |
| Sex: Female, Male(Participants) | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Total |
|---|---|---|---|---|---|
| Stage 1 — Female | 144 | 333 | 152 | 289 | 918 |
| Stage 1 — Male | 128 | 201 | 119 | 234 | 682 |
| Stage 2 — Female | 28 | 26 | 47 | 29 | 130 |
| Stage 2 — Male | 39 | 14 | 30 | 27 | 110 |
| Ethnicity (NIH/OMB)(Participants) | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Total |
|---|---|---|---|---|---|
| Stage 1 — Hispanic or Latino | 35 | 73 | 24 | 61 | 193 |
| Stage 1 — Not Hispanic or Latino | 236 | 461 | 246 | 461 | 1404 |
| Stage 1 — Unknown or Not Reported | 1 | 0 | 1 | 1 | 3 |
| Stage 2 — Hispanic or Latino | 6 | 3 | 3 | 1 | 13 |
| Stage 2 — Not Hispanic or Latino | 61 | 37 | 74 | 55 | 227 |
| Stage 2 — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1: MenABCWY + Saline (ACWY-Naive) | Group 2: Bivalent rLP2086 + MenACWY-CRM (ACWY-Naive) | Group 3: MenABCWY + Saline (ACWY-Experienced) | Group 4: Bivalent rLP2086 + MenACWY-CRM (ACWY-Experienced) | Total |
|---|---|---|---|---|---|
| Stage 1 — American Indian or Alaska Native | 10 | 13 | 6 | 20 | 49 |
| Stage 1 — Asian | 1 | 4 | 3 | 8 | 16 |
| Stage 1 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Stage 1 — Black or African American | 27 | 53 | 25 | 60 | 165 |
| Stage 1 — White | 234 | 464 | 237 | 435 | 1370 |
| Stage 1 — More than one race | 0 | 0 | 0 | 0 | 0 |
| Stage 1 — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Stage 2 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Stage 2 — Asian | 0 | 0 | 0 | 1 | 1 |
| Stage 2 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Stage 2 — Black or African American | 5 | 3 | 4 | 2 | 14 |
| Stage 2 — White | 59 | 37 | 72 | 53 | 221 |
| Stage 2 — More than one race | 0 | 0 | 0 | 0 | 0 |
| Stage 2 — Unknown or Not Reported | 3 | 0 | 1 | 0 | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Apr 2017 to primary completion in Oct 2022, 66 months.
Results were first posted in Aug 2023, 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Meningococcal pentavalent vaccine · MenB-FHbp vaccine · 4CMenB vaccine